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ABSTRACT 
 
Cocaine and opioid abuse are a major public health concern and the cause of significant 
morbidity and mortality worldwide. The development of effective medication for cocaine and 
opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The 
pharmacologic treatment for drug abuse has been based on one of the following strategies: 
agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused 
on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, 
CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor 
agonists), for the treatment of drug abuse.  
The affinity of cocaine to sigma-1 receptors render the hypothesis that targeting sigma-1 
receptors using antagonists will be an effective strategy in the development of novel medications 
for cocaine abuse. In this light, we screened several sigma-1 receptor antagonists using in vitro 
metabolism studies and selected CM304, (3-(2-(azepan-1-yl) ethyl)-6-(3-fluoropropyl) 
benzo[d]thiazol-2(3H)-one), as a lead compound. CM304 was further characterized by 
determining its physicochemical properties such as pKa, Log PO/W and Log D PBS, pH 7.4, solubility, 
protein binding, in vitro metabolic stability. We also investigated pharmacokinetic parameters 
and bioavailability of CM304 in rats using a validated UPLC-MS/MS method.   
Mitragyna speciosa Korth is a tropical plant indigenous to Southeast Asia. The leaves of 
the plant have been used as a traditional medicine to treat cough, fever, diarrhea, pain, 
hypertension and morphine addicts. Mitragynine and 7-hydroxymitragyne, corynanthine-like 
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alkaloids, have been reported to be responsible for the opioid properties found in this plant. We 
have developed simple, sensitive and high throughput bioanalytical methods for the 
quantification of mitragynine and 7-hydroxymitragyne in rat plasma. Pharmacokinetic 
parameters were evaluated by conducting single dose in vivo pharmacokinetic studies in rats. The 
extent of brain penetration of 7-hydroxymitragyne in rats was determined by performing an in 
vivo brain to plasma ratio.  
The above in vitro and in vivo experiments discussed on this dissertation will lay the 
groundwork for further development of these compounds as pharmacotherapies for cocaine and 
opioid abuse. 
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CHAPTER - 1 
INTRODUCTION 
1.1. Cocaine 
The abuse of drugs and alcohol is a serious universal problem. Drug addiction is 
considered to be a chronic, relapsing disorder characterized by an uncontrollable drug craving 
regardless of serious health problems [1, 2]. Repeated drug use arises due to the positive 
reinforcing effects produced by drugs that lead to neurological changes in the brain’s reward 
circuits [1, 3]. Drug addiction has also been reported to involve another source of reinforcement 
such as, withdrawal symptoms. Positive (e.g., euphoria) and negative (e.g., withdrawal 
symptoms) reinforcement together provide a strong motivational force for obsessive drug intake 
leading to addiction [2]. The neurological changes and behavioral abnormalities that are 
associated with drug addiction may persevere for months or years after termination of drug use. 
The characteristic behaviors of addiction include tolerance, sensitization, dependence, 
withdrawal and craving [1]. 
Cocaine is one of the oldest and most powerful psychoactive substances. It is widely 
abused and perhaps the most reinforcing of all drugs of abuse [4, 5]. Coca leaves, the natural 
source of cocaine have been chewed and ingested for thousands of years and cocaine 
hydrochloride has been an abused substance for more than 100 years [5, 6]. Cocaine was used in 
early 1900s to treat chronic pain, asthma, wasting diseases, and nervous exhaustion and was also 
used as a local anesthetic during surgical procedures [7]. Cocaine is available in 2 chemical 
forms: the water-soluble hydrochloride salt and the water-insoluble base (or freebase). The 
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powder cocaine or the hydrochloride salt can be snorted or injected. Snorting involves inhaling 
powder cocaine through the nose and injecting uses a needle to deliver the drug directly into 
systemic circulation. The free base is processed to produce a smokable substance called crack. 
Crack is an alkaloid form of cocaine freebase and the name refers to the crackling sound heard 
when it is heated. Crack cocaine is often injected or smoked but rarely snorted [8]. The principal 
routes of cocaine administration are oral, intranasal, intravenous, and inhalation [5].  
Globally, cocaine use is considered to be concentrated in Western Europe and the 
Americas, but it is thought to be spreading quickly geographically. In the latest World Drug 
Report, the United Nations Office on Drugs and Crime (UNODC) reported that cocaine 
consumption has increased in Europe and some West African countries over the past decade [8]. 
In 2007, nearly 14% of United States population over the age of 12 used cocaine at least once.  
Cocaine use is associated with several acute and chronic adverse effects [8]. After a 
single dose, the effects begin immediately and disappear within a few minutes or hour. When 
consumed in small amounts, cocaine typically causes the user to feel euphoric, energetic and 
mentally alert. Its use can also temporarily decrease the need for food and sleep [6]. The duration 
of these effects depends upon the route of administration. Snorting cocaine produces a relatively 
slow onset of the effect but it may last 15 to 30 minutes; in contrast, the effects from smoking are 
immediate but last only 5 to 10 minutes. The powerful central nervous system (CNS) stimulation 
caused by cocaine is followed by depression [4, 7, 9]. However, the exact physiology related to 
depression after using cocaine is unknown, but it has been linked to catecholamine or other 
neurotransmitter depletion. Cocaine washout syndrome has been used to describe the result of 
chronic cocaine use and is manifested by a severe state of hypoactivity. Individuals with washout 
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syndrome can behave listless, lethargic and unresponsive and their mental status can vary from 
drowsiness to deep coma [10]. 
The short-term physiological effects of cocaine use include: constricted blood vessels, 
dilated pupils, and increased heart rate, blood pressure, and body temperature. Some users 
experience restlessness, irritability, anxiety, and paranoia. Severe medical complications are also 
associated with cocaine use including cardiovascular effects (cardiac arrhythmia and heart 
attacks), neurological effects (strokes, seizures, headaches, and coma) and gastrointestinal 
complications (abdominal pain and nausea). In rare cases, sudden death can occur on the first use 
of cocaine or unexpectedly thereafter. This is often a result of cardiac arrest or seizures followed 
by respiratory arrest [5, 8, 11]. When cocaine is consumed repeatedly the brain starts to adapt 
and the reward pathway becomes less sensitive to natural reinforcers and to the drug itself. This 
leads to tolerance. At the same time, users may also develop sensitization to the drug. The risk of 
cocaine adverse effects increases with increasing doses or frequency of administration. 
Additionally, due to the use of cocaine in shooting galleries and sharing of injection equipment, 
cocaine addiction has been associated with increased risk of HIV, hepatitis B and C and violence 
[11, 12]. The disastrous health and social consequences of cocaine abuse made the development 
of an effective treatment a high priority. However, there is still no FDA approved therapeutic 
agent for treating cocaine abuse [11, 13].  
1.2. Current investigations for pharmacotherapy to cocaine addiction 
The foremost objective of drug abuse research is to develop successful treatment 
strategies. One strategy for the treatment of addiction primarily focuses on the use of compounds 
that substitute for the actions of the abused drug and have a longer duration of action with 
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minimal abuse potential and fewer side effects [14, 15]. Other important criteria for a successful 
therapeutic candidate includes slow onset of action and long-lasting effects with a slow offset of 
action.  As the chronic use of cocaine causes abiding changes in the brain, use of the drug that 
reverses the damage induced by the obsessive intake of the cocaine would be the most logical 
way in treating addiction [16]. Moreover, the compound should block the acute reinforcing and 
euphorogenic effect of cocaine, and suppress the intense craving associated with the cocaine 
abstinent state [17]. Cocaine addiction is very complex and it is difficult to break the cycle of 
dependence for most victims [18].  
Cocaine addiction has been the main focus of multidisciplinary research ranging from 
molecular and preclinical behavioral studies to clinical trials. Despite the continued research and 
huge advances in the neuroscience of substance abuse and dependence, no FDA approved 
medication is available to treat cocaine addiction. Some of the promising targets for cocaine 
pharmacotherapy are summarized below including dopaminergic, serotonergic and GABA 
medications, adrenoceptor antagonists, vasodilators and immunotherapies. 
1.2.1. Dopaminergic medications  
Numerous studies suggest that the brain’s dopamine system is vital in mediating the 
rewarding and addictive effects of cocaine [19]. The dopamine system is formed by the 
dopamine neurons originating from the ventral tegmental area of the midbrain that target a 
number of limbic and cortical structures such as the nucleus accumbens, the area involved in 
reward [20]. The classic mechanism of action of cocaine involves its interaction with dopamine 
(DA). Cocaine binds to dopamine transporters and blocks the reuptake of DA resulting in the 
buildup of DA in the synapse. This increases in DA levels leads to the pleasurable as well as 
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rewarding effects of cocaine. Pharmacologically the dopamine receptors are classified in to two 
subtypes: dopamine D1-like and dopamine D2-like. The D1-like family includes D1 and D5 
receptors which stimulate cyclic adenosine mono- phosphate (cAMP) formation. The D2-like 
family includes D2, D3 and D4 receptors which inhibit the cAMP formation [21]. D1 as well as 
D2-like receptors have been proposed to mediate the acute and chronic effects of cocaine. Some 
of the dopaminergic compounds that were tested for the treatment of cocaine addiction are 
methylphenidate, mazindol, amantadaine, selegelline, disulfiram, ecopipam and bromocriptine. 
The most promising findings were seen with disulfiram [22].  
Disulfiram inhibits dopamine β-hydroxylase (DBH) that converts DA to norepinephrine 
leading to increased DA levels in the brain [23]. A recent study has shown that the co-
administration of disulfiram with cocaine increased the plasma cocaine concentrations 3 to 6 
fold, which perhaps contributed to the decreased craving and increased dysphoria observed 
during the study. In a more recent study, Carroll et al. showed a greater reduction in cocaine use 
with disulfiram 250 mg/day administration. These findings suggest that disulfiram may be an 
effective medication to treat cocaine abuse [22, 24]. Nevertheless, additional studies are needed 
to determine the optimal dose and duration of treatment with this compound. 
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Figure 1.1: Classical mechanism of action of cocaine [25] 
Reprinted with kind permission from American Chemical Society 
 
1.2.2. GABA system 
Currently the Gamma-amino butyric acid (GABA) system is receiving increasing 
attention as a promising target for the pharmacotherapy of cocaine dependence [26]. GABA is a 
widely distributed neurotransmitter that mediates inhibition in the brain. GABA receptors are 
classified in to 2 types GABAA and GABAB. The activation of GABAA receptors decreases 
neuronal excitability by increasing chloride influx where as GABAB receptors mediate the slow 
inhibitory response to GABA [22]. GABAergic synapses are present in the brain areas such as 
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striatum and nucleus accumbens that are rich in dopaminergic neurons suggesting anatomical 
connectivity between these two systems [27]. It was shown that treatment with vigabatrin 
(gamma-vinyl-GABA), which increases GABA levels, attenuated cocaine induced locomotor 
activity and dopamine release in the nucleus accumbens in rats [28, 29]. Overall, these findings 
suggest that the GABA system may be a potential target for cocaine pharmacotherapy.  
Other GABA medications that have been tested for cocaine pharmacotherapy are valproic 
acid, tiagabine, topiramate, baclofen, gabapentin, progesterone and some of these drugs showed 
promising effects in clinical trials [22, 30]. Baclofen, a selective GABA-B agonist used as an 
antispasmodic in spinal cord injuries or multiple sclerosis, is the most promising compound 
available for studies in humans. Baclofen was shown to attenuate cocaine seeking behavior in 
rodents and inhibit self-administration of cocaine dose-dependently [31]. A randomized, double-
blind, placebo-controlled trial in 70 cocaine-dependent patients conducted by Shoptaw et al. 
showed significant reductions in cocaine use in baclofen treated subjects than those receiving the 
placebo. Baclofen seems to be well tolerated with no significant side effects. However, the short 
half-life (3–4 h) would be the major limitation because of the poor compliance in patients with 
cocaine-related problems. Topiramate is a licensed antiepileptic drug, that may perhaps control 
dopamine release in the nucleus accumbens by blocking the excitatory effects of glutamatergic 
neurons and enhancing GABAergic inhibitory activity [32]. In several studies topiramate showed 
no serious adverse effects. 
1.2.3. Glutamate 
L-Glutamate is one of the major excitatory neurotransmitter in central nervous system 
(CNS). Glutamate plays important role in several physiological processes such as neuronal 
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growth, and plasticity, cognitive and motor behavior, depression, anxiety, drug abuse and 
neurotoxicity. Glutamate mediates its physiological and pharmacological effects through 
ionotropic (N-methyl-D-aspartic acid, NMDA) and a group of metabotrpoic receptors. Chronic 
use of cocaine diminishes extracellular glutamate levels and reduces glutamatergic synaptic 
strength in the nucleus accumbens. Few ionotropic ligands have been introduced for clinical use 
in neurodegenerative disorders and are now being tested for pharmacotherapy of cocaine 
addiction [33].  
Various N-methyl-D-aspartic acid (NMDA) receptor antagonists such as memantine, 
ibogaine, lamotrigine have been shown to have the potential to counteract relapse and drug-
seeking behavior in animals. They also inhibit dopamine receptor sensitization, which usually 
seen in cocaine addiction, by preventing its development [34]. Memantine was shown to inhibit 
cocaine self-administration in rats. Ibogaine was reported to reduce craving for cocaine and 
heroin in addicted polydrug users. In a recent study, Dackis et al. proposed that modafinil, a 
glutamate agonist, promotes cocaine abstinence by reversing cocaine-induced dopamine 
dysregulation restoring the levels of glutamate in the nucleus accumbens [13].  
1.2.4. Serotonergic receptors 
Cocaine has high affinity to serotonin (5-HT) receptors. Simultaneous administration of 
cocaine with clozapine resulted in increased locomotor activity and release of dopamine and 5-
HT in the nucleus accumbens. Patricia et al. has shown that cocaine-rewarding effects were 
diminished in homozygous dopamine and serotonin-transporter knocked out mice [35]. It was 
reported by Walsh et al. and Kampman et al. that the manipulation of the serotonergic system 
relieves drug craving in humans. Even though the results were inconclusive, these studies 
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suggest the importance of serotonergic agents in the development of pharmacotherapies to treat 
cocaine abuse and addiction [36]. Several studies have shown that the activation of 5-HT3 
receptors partially mediates the reinforcing effects of cocaine in posterior ventral tegmental area 
[13, 37].  Ondansetron, a selective 5-HT3 receptor antagonist, is an antiemtic used for nausea 
induced by cancer treatment and anesthesia. Administration of ondansetron during the acute 
cocaine withdrawal phase attenuated cocaine self-administration in animals [13, 38].  
1.2.5. Adrenoceptor antagonists 
Cocaine also activates the adrenergic system including the central noradrenergic system, 
its peripheral counterpart, and the sympathoadrenal system. It has been shown that the adrenergic 
system plays an inportant role in mediating the physiological response to cocaine, including 
increases in heart rate, blood pressure and arousal [39]. Adrenoceptor antagonists have inhibited 
some of the behavioral and toxic effects of cocaine in rats, suggesting its role in mediating 
cocaine effects [40]. Propranolol, carvedilol and labetalol are few of the adrenoreceptor 
antagoniststhat have been tested for cocaine treatment. 
A recent study has shown that an acute treatment with 50 mg of carvedilol attenuated the 
cocaine induced changes in heart rate, systolic and diastolic blood pressure. However, self-
administration of cocaine was found be decreased when the subjects received carvedilol at a dose 
of 25 mg rather than 50 mg. Based on these results, it was proposed that β-adrenoceptor 
antagonists may attenuate the reinforcing effects of cocaine. However, further studies are needed 
to confirm the use of adrenoceptor antagonists for the treatment of cocaine addiction [22, 41]. 
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1.2.6. Vasodilators 
Cocaine users generally exhibit reduced cerebral blood flow and cortical perfusion 
deficits with areas of both hypo and hyper perfusion [42]. This reduced cerebral flow seems to be 
associated with some of the neuropsychological impairments in verbal learning, memory and 
attention witnessed in cocaine addiction [22]. Isradipine, a calcium channel blocker used in 
treatment of hypertension, attenuated various cocaine induced responses like ischemic changes in 
the brain and altered systolic blood pressure [43, 44]. 
1.2.7. Vaccines 
One of the approaches to permanently reduce the reinforcement effects of cocaine re-
exposure is to block the entry of cocaine into brain [4, 18]. This can be achieved with antibodies 
evoked by a therapeutic vaccine, as IgG-bound drug cannot cross the blood-brain barrier. The 
utilization of this approach to treat cocaine addiction efficiently requires a good understanding of 
the mechanisms of antibody blockade and the immunological parameters that regulate the 
development and persistence of antibody responses [18, 22]. Several investigations on 
noradrenergic, adrenergic and muscarinic mechanisms suggests that they may be less favorable 
targets for development of a therapeutic candidate due to limited efficacy and/or unfavorable 
side effect profiles. Therefore, current studies have targeted the most recently discovered of these 
sites, the sigma receptor.  
1.3. Introduction to sigma receptors 
Sigma receptors have gained much attention in recent years with their involvement in 
various neurological disorders, drug addiction and cancer. Initially sigma receptors were 
11 
 
identified as a subtype of opioid receptors. Based on behavioral studies of morphine-like drugs in 
dogs, Martin and co-workers named this distinct class of receptor as ‘sigma’ [45]. The sigma 
receptors were earlier confused with the PCP (phencyclidine)/NMDA receptors as a number of 
ligands for these individual receptors cross-reacts with the other receptor. However, the 
confusion was clarified with the discovery of more selective drugs for these receptors, such as 
dizocilpine or thienylcyclidine for PCP and 1,3-di-O-tolylguanidine (DTG), (+)-pentazocine, 
igmesine for sigma [46, 47]. Subsequent studies clearly demonstrated that sigma receptors are a 
unique class of binding proteins with a distinct ligand selectivity pattern and specific anatomical 
distributions from other proteins [48-50].  
Numerous drugs of different classes have a high binding affinity to sigma receptors, these 
include psychotomimetic benzomorphans, cocaine and its derivatives, amphetamine, some 
neuroleptics, atypical antipsychotic agents, anticonvulsants, monoamine oxidase inhibitors, 
histaminergic receptor ligands, and several steroids [51, 52]. These compounds led to the 
pharmacological identification of sigma receptors as unique receptors differentiating them from 
opioid receptors. The autoradiographic localization of sigma receptor binding sites was 
accomplished using a range of radioligands, such as [
3
H](+)-SKF-10,047, [
3
H](+)-3-PPP [3-(3-
Hydroxyphenyl)-N-(1-propyl)piperidine], [
3
H]haloperidol, [
3
H]DTG, [
3
H](+)-pentazocine [47, 
50, 53]. 
[
3
H](+)-3-PPP is a selective DA autoreceptor agonist. As it binds to the sigma receptors, 
this compound was used to localize the sigma receptor binding sites [54]. Andrew et al. 
determined the binding sites of [
3
H](+)-3-PPP in brain and spinal cord of both guinea pig and rat 
by in vitro autoradiography. They showed that [
3
H](+)-3-PPP binds with  high  affinity  to  brain  
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membranes with highest concentrations in spinal cord, the pons-medulla, the cerebellum and 
hippocampus. [50]. 
To date, two subtypes of sigma receptors have been identified, sigma-1 and sigma-2, 
based on their respective size, distribution in various tissues and affinity for enantiomers of 
benzomorphans [55, 56]. These receptors are abundantly distributed in several brain areas and 
also in various peripheral tissues. Of the two established sigma receptor subtypes, the sigma-1 
receptor has been purified and cloned from several species, including mouse, rat, guinea pig and 
human [57-59]. The sigma-1 receptor has 223 amino acids with two transmembrane-spanning 
regions [60]. The sequence of amino acids in sigma receptors render them unique from other 
mammalian proteins [57]. Unlike sigma-2 receptors, sigma-1 receptors are predominantly 
distributed in the heart and spleen where the actions of sigma-1 are presumed to dominate over 
those of the sigma-2 subtype [61]. The sigma-2 receptor is less well characterized and its protein 
has not yet been cloned but few specific ligands have been described in literature [62, 63]. 
Sigma-1 and sigma-2 receptors can be demarcated based on their diverse drug selectivity and 
molecular weights. The sigma-1 receptors exhibit a high affinity and stereoselectivity for (+)-
isomers of pentazocine and cyclazocine, while sigma 2 receptors demonstrate lower affinity and 
show the reverse stereoselectivity. Compounds like 1,3-di-O-tolylguanidine (DTG), and 
haloperidol show high affinity for both subtypes [47]. 
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Figure 1.2: A structural model for the sigma-1 receptor [64] 
Reprinted with kind permission from Elsevier (License Number: 2873430447566) 
1.3.1. Effects of sigma-1 receptor ligands in animal models  
1.3.1.1. Drug induced amnesia 
Selective sigma-1 agonists have been shown to improve amnesia induced by the NMDA 
receptor, Ca
2+
 channel, acetylcholine muscarinic and nicotinic receptor antagonists suggesting 
their role in treating amnesia [65]. In addition, it was found that sigma-1 receptors regulate 
release of intracellular Ca
2+
 from Ca
2+ 
storage sites. Furthermore, the injections of intracellular 
Ca
2+ 
release inhibitors were shown to eliminate the effects of sigma-1 receptor agonists [66].  
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1.3.1.2. Depression and anxiety 
The effects of sigma-1 ligands were recently explored in animal models looking at  
depression. Forced swim test (FST) is a most widely used behavioral test to evaluate the efficacy 
of antidepressant drugs in rats or mice. Briefly, the test animals will be placed inside a 
transparent cylinder containing water for 15 min on day 1 followed by 6 min on day 2. 
Immobility of the rat during last 5 minutes will be recorded. Placing rodents in the water leads to 
a characteristic behavior called immobility, in which the animals make only those movements 
which are necessary to keep their head above water. The behavioral immobility is selectively 
decreased when antidepressants are administered [67]. Different classes of sigma agonists such 
as (+)-pentazocine, SA-4503 and igmesine dose-dependently reduced the immobility time in the 
mouse FST. This activity was blocked by NE-100, a sigma receptor antagonist [66, 68]. Gue et 
al. stated that augmentation of colonic spike bursts induced by conditioned fear stress or 
corticotropin releasing hormone can be attenuated by igmesine, a sigma-1 receptor agonist. Their 
findings are pertinent in regard to gastrointestinal tract disorders observed in anxiety and mood 
disorders [66, 69]. However more studies are needed to confirm their role in anxiety. 
1.3.1.3. Drug-dependence and analgesia 
Several studies indicated that analgesia induced by opioids can be inhibited by sigma-1 
receptor agonists [70]. This was supported by presence of sigma-1 receptors in spinal cord and 
peripheral nerves which are enriched with opioid receptors. Thus sigma ligands were shown to 
control the activities of opioid receptors at these locations. Matsumoto et al. confirmed that low 
doses of novel sigma receptor antagonists could notably inhibit convulsions and lethality induced 
by toxic doses of cocaine. In addition, the cocaine toxicity was augmented by sigma-1 receptor 
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agonists, indicating the likely involvement of sigma-1 receptors in cocaine-induced toxicity [71, 
72]. 
1.3.2. Pharmacological potentials and clinical uses of sigma receptor ligands 
The involvement of sigma receptors in various neurological disorders remains unclear to 
date. Because of the interactions of sigma receptors with many psychoactive ligands such as 
cocaine, sigma ligands have gained special attention as potentially useful antipsychotics, 
antidepressants, anxyolitics, antiamnesics, analgesics, antiepileptics, anticonvulsants, and 
neuroprotective agents [73-75]. 
Besides their involvement in neurological disorders and variety of CNS diseases, sigma 
ligands might become promising candidates for treating cancer.  The cytotoxicity of both sigma-
1 and sigma-2 ligands is well documented, categorizing them as potential anti-tumor agents [76, 
77]. Due to the over expression of sigma receptors on tumor cells, sigma ligands can be 
preferentially used as PET (Positron Emission Tomography) imaging agents for the visualization 
of tumor cell proliferation [78]. Radiotracers containing 
123
I, 
124
I, 
125
I, 
18
F, 
99
mTc, and 
11
C sigma 
ligands were studied as PET imaging agents. This technique might result in early and cost- 
effective diagnosis of tumors with widespread availability [79].  
Another most important application of sigma receptor ligands is in the treatment of 
cocaine abuse and addiction. Both sigma-1 and sigma-2 receptors are thought to be involved in 
the anti-cocaine activity. However, only the involvement of the sigma-1 receptors is well 
documented [47].  
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1.4. Morphine  
The medicinal value of opium has been agreed on for centuries. In spite of having an 
extensive side-effect profile, morphine, isolated from opium, remains the gold standard for 
treating chronic or persistent pain. Activation of the µ-opioid receptors located in the regions of 
brain and spinal cord that transmit pain are responsible for the majority of the physiological and 
behavioral effects of morphine [80-82] Morphine is a lipophilic compound and is available as 
sulphate, tartrate and hydrochloride salt. Its average bioavailability is 20-30% in healthy humans 
and cancer patients as well [82]. Morphine has been considered the drug of choice for treating 
moderate to severe pain. Its short half-life allows frequent changes in dosing according to the 
individual needs. The low cost of morphine solution and immediate-release formulations and its 
potential availability are the major reasons for it to be recommended as a first-line opioid in the 
WHO Cancer Pain Relief Guidelines [83]. 
However, its narrow therapeutic index and severe side effects limit its therapeutic use. 
The most prominent side effects are respiratory depression, decreased gastrointestinal motility 
and the development of dependence, withdrawal symptoms after chronic administration [84]. In 
therapeutic doses morphine also causes euphoria, sedation, nausea and vomiting. Reduction of 
these side effects would enhance the therapeutic potential of morphine [82]. One of the major 
side effects of morphine administration is development of tolerance to the analgesic effect [81]. 
Adaptation process can be one of the underlying causes of tolerance to opioids. The sources for 
adaptation can be traced back to the cellular and molecular level.  
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1.4.1. Receptor related changes involved in tolerance 
 Most common effects of opioid administration initially are analgesia, sedation, 
nausea/vomiting, respiratory depression, pupillary constriction, constipation and euphoria or 
dysphoria. Opioids show selective tolerance i.e. tolerances to different opioid effects develop at 
different rates. While tolerance to nausea, vomiting, sedation, euphoria and respiratory 
depression occur immediately, the tolerance to constipation and miosis is minimal. This diversity 
suggests receptor-related differences in the rate of development of tolerance to opioids.  
1.4.2. NMDA activation, opioid receptor internalization and desensitization 
 Another underlying mechanism for tolerance is internalization or endocytosis of the 
opioid receptors which results in the decrease of binding sites available for the mediation of 
analgesia. Nevertheless, morphine induced internalization of opioid receptors seems to be 
specific for certain neurons in the brain and more specifically some regions of neurons like 
dendrites or axons.   
A sudden withdrawal after chronic treatment with morphine leads to the development of 
many withdrawal symptoms. The locus ceruleus (LC) which is highly enriched in noradrenergic 
neurons is associated with the manifestation of morphine withdrawal. Morphine withdrawal also 
reduces the dopaminergic activity leading to many of the dysphoric and anhedonic effects that 
are associated with withdrawal. Continued abstinence from morphine use results in drug craving 
and relapse [81]. 
To overcome its side effects, several researchers tried to develop morphine substitutes 
with high analgesia and without addicting properties. Unfortunately it was proved that the 
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chemical modification which led to high analgesia resulted in increased dependence and 
addiction potential. Due to the structural similarities between morphine and its congeners, both 
bind primarily to the same receptor subtypes (μ-opioid receptors).  
The common clinically-used morphine analogues are oxymorphone, oxycodone, heroin, 
codeine, hydrocodone, hydromorphone and levorphenol. Oxycodone is a synthetic derivative of 
morphine with fewer side effects and lower probability to hallucinations than morphine, yet its 
addictive properties are similar to morphine [85].  Oxymorphone is 10-14 times more potent than 
morphine but the tolerance towards oxymorphone develops to a higher extent than morphine [86, 
87]. The currently available semisynthetic and synthetic opioids have favorable properties than 
morphine but they still possess undesirable properties of morphine [82]. 
1.5. Role of pharmacokinetics and metabolism in drug discovery 
As pharmacokinetics (PK) and drug metabolism are the major determinants contributing 
to the success in drug development, many drug companies have included the evaluation of 
absorption, distribution, metabolism and elimination (ADME) as part of the screening processes 
in drug candidate selection [88, 89]. The primary objective of these studies is to eliminate the 
molecules with undesirable properties at the very early stages of drug development. This greatly 
eliminates the attrition resulting from inadequate clinical PK [90]. Much of the failures of drug 
candidates in development processes can be ascribed to the unsatisfactory pharmacokinetic 
properties, such as too long or too short half-life (t1/2), poor absorption, and extensive first-pass 
metabolism [91]. For a drug candidate to be successful, it is essential that it possess good 
bioavailability and a desirable t1⁄2. Therefore, an accurate estimate of the pharmacokinetic and 
metabolic data and a good understanding of the factors that affect these properties will guide 
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drug design [88, 91]. To obtain desirable pharmacokinetic and pharmacological properties, this 
data must be available almost as early as the results of the in vitro screening.  
Comprehensive information on the metabolic processes and pharmacokinetics of the new 
drug candidate is always required by regulatory agencies. An understanding of the kinetics of 
metabolite formation is important to foresee the therapeutic outcome and to explain the toxicity 
of specific drugs. The metabolism of new drug candidates should be studied preferably in vitro 
before the clinical studies. Early information on in vitro metabolic processes, such as 
identification of metabolites, and drug metabolizing enzymes involved in the metabolism are 
useful in the design of clinical studies [91]. Advantages of in vitro studies in early drug 
discovery include high capacity at low cost, manipulability for mechanistic studies and 
prediction of clinical outcomes qualitatively. The lack of ability to quantitatively predict the 
clinical results necessitated the validity of in vitro data in the context of its correlation with in 
vivo data. Consequently, drug candidates are often evaluated for their PK and metabolic 
pathways in preclinical species. Rodents usually are used during initial screening. The key 
parameters estimated from these PK screenings include oral bioavailability (F), terminal half-life 
(t1/2), clearance (CL) and volume of distribution (Vd). These parameters are highly informative 
and are useful in predicting the causes for poor performance of the compound in vivo such as, a 
high CL and low F indicate extensive first-pass elimination, high CL plus high F implicate extra-
hepatic elimination, and low F with low CL suggest poor oral absorption. Disadvantages of 
preclinical PK screening are heavy investment of resources and a lack of correlation with 
humans [90].  
Identification of the “soft spots” for the molecules exhibiting high clearance is one of the 
objectives of ADME studies in drug discovery. These experiments are usually performed in vitro 
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using similar protocols as in metabolic stability screening, and metabolites are identified by LC-
MS/MS in combination with NMR analysis. Recently, the identification of reactive metabolites 
has been added to the list of ADME studies. The electrophiles resulting from drug metabolism 
lead to covalent modification of proteins, causing toxicity via disruption of cellular functions. 
Early identification and elimination of molecules that undergo metabolic bioactivation perhaps 
reduce the probability of idiosyncratic drug toxicity that occurs in the late stage of development 
such as phase II trials [91]. 
Following figure summarizes the common issues seen in drug discovery that arise 
because of the undesirable ADME properties, and the experiments typically used to estimate 
them. These in vitro and in vivo experiments serve as valuable tools in lead optimization. 
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Figure 1.3: In vitro and in vivo experiments that are used to address common issues  in potential 
small molecule drug discovery [92] 
Reprinted with kind permission from John Wiley and Sons (License Number: 2873430866673) 
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CHAPTER - 2 
PRECLINICAL CHARACTERIZATION OF CM304, A NOVEL AND HIGH AFFINITY 
SIGMA-1 RECEPTOR LIGAND WITH POTENT ANTI-COCAINE ACTIONS 
 
2.1. Introduction 
Sigma-1 receptors are widely distributed in peripheral organs including liver, lung, spleen 
and heart but are also highly expressed in the central nervous system (CNS) [61, 93]. Sigma-1 
receptor are chaperone proteins that modulate inositol 1,4,5-triphosphate (IP3) receptor-mediated 
Ca
2+
 signaling at mitochondrion-associated endoplasmic reticulum membrane [94, 95]. Sigma-1 
receptors exert modulatory functions on dopamine, acetylcholine, NMDA, and opioid receptors. 
Sigma-1 receptors also modulate potassium channels in nerve terminals, the N-methyl-d-
aspartate-induced neuronal firing, and dopamine release in the brain [96-98]. Moreover, sigma-1 
receptors are implicated in complex neurological processes including pain, depression, addiction 
to cocaine or methamphetamine, dementia, schizophrenia, and anxiety [46, 99-101]. They also 
play an important role in the digestive function, cancer and several neurodegenerative disorders 
such as Parkinson’s and Alzheimer’s diseases [102, 103]. Sigma-1 receptors are highly expressed 
in most known cancers (e.g., breast, lung, colon, ovarian, prostate, brain) [104, 105]. They are 
implicated in complex neurological processes including depression, dementia and addiction to 
cocaine. Consequently, sigma-1 receptors are recognized as a potential target for the 
development of new therapeutic drugs and diagnostic imaging agents for CNS diseases. 
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A wide variety of compound classes with diverse structures possess a high affinity for 
sigma-1 receptors. These include different psychotherapeutic agents, drugs of abuse such as 
cocaine and methamphetamine and steroid hormones such as progesterone. It has been observed 
that the common pharmacophoric element in compounds that binds to sigma-1 receptors is a 
“basic nitrogen” atom [106]. 
This project was initiated from SN56, (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-
2(3H)-one),  a novel sigma-1 selective benzothiazolone class of compound. SN56 was previously 
reported to have sub-nanomolar affinity (Kiσ1=0.56 nM) and more than 1000 fold selectivity for 
sigma-1 receptors relative to sigma-2 receptors. When tested against a panel of receptors (D1, 
D2, 5-HT, α1, α2, β1, β2, H1 and H2), SN56 exhibited 350 times greater affinity for the sigma-1 
receptors [107]. However, this compound lacked the stability (In vitro t½, 1.2 ± 0.2 min) required 
in a clinical development candidate. In order to overcome its poor metabolic stability, a series of 
analogues (RB7-31019, RB-55-11, RB5-213-29, RB5-79, RB5-219-41 and CM304) were 
synthesized by slightly modifying the structure of SN56. These modifications were aimed at 
developing a more stable compound while retaining the high affinity and selectivity for sigma-1 
receptors.  
 
Figure 2.1: Chemical structure of SN56 
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2.2. Experimental  
2.2.1. Materials 
SN56 and analogs (RB7-31019, RB-55-11, RB5-213-29, RB5-79, RB5-219-41 and CM304) 
were synthesized by Dr. Christopher McCurdy’s research group, Department of Medicinal 
Chemistry, University of Mississippi. SN56 was synthesized as previously reported by Yous et 
al., [107]. All of the analogs were analyzed by 
1
H NMR, 
13
C NMR, elemental analysis and HR-
MS, and were found to be pure (> 99%). Methanol, acetonitrile and water were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  Formic acid was obtained from Mallinckrodt Baker Inc. 
(Phillipsburg, NJ, USA). Rat plasma was purchased from Innovative Research (Peary Court 
Novi, MI, USA). All solvents used were HPLC grade. 
2.2.2. In vitro metabolism studies  
The metabolic stability of a new chemical entity determines its future as a clinical drug 
candidate. By determining the time versus parent disappearance and/or metabolite formation in 
vitro in an appropriate system, one can predict the hepatic clearance in vivo. Metabolic stability 
is also an important contributor in optimizing the pharmacokinetic profile [91]. 
To develop a metabolically stable sigma-1 receptor ligand a series of analogs (RB7-
31019, RB-55-11, RB5-213-29, RB5-79, RB5-219-41 and CM304) were synthesized by masking 
the metabolic “weak spots” on SN56. Microsomal metabolic stability of the analogs was 
estimated in pooled rat liver microsomal preparations by monitoring disappearance of the parent 
compound over an incubation period of 60 min. Detailed procedure of in vitro liver microsomal 
stability study was explained in section 2.3.4. 
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2.3.  Preclinical characterization of CM304 
2.3.1. Instrument and chromatographic conditions 
The chromatographic separation was carried out on a Waters Acquity ultra-performance 
liquid chromatography (Waters Corp., Milford, MA, USA) equipped with a binary solvent 
manager, vacuum degasser, thermostatted column compartment, and an auto-sampler. A Waters 
Acquity UPLC
TM
 BEH C18 column (1.7 μm, 2.1 mm×50 mm) was used for all the separations. 
The mobile phase (pH, 3.2) consisted of 0.1% formic acid in water and 0.1% formic acid in 
methanol (50:50, v/v) and was pumped at a flow rate of 0.2 mL/min. The column temperature 
was maintained at 25 ºC and the injection volume was 10 μL. These parameters resulted in a 
total run time of five minutes per injection. 
Mass spectrometric analysis was performed using Waters Micromass quattro MicroTM
 
triple-quadrupole system (Manchester, UK) equipped with an electro-spray ionization (ESI) 
source. The system was controlled by MassLynx software version 4.1. The detection was 
achieved with ESI positive ionization using multiple reaction monitoring (MRM). The MS/MS 
parameters for the analysis were as follows: capillary voltage 4.86 kV, cone voltage 25 V, 
extractor voltage 5 V, RF lens voltage 0.5 V. The source and desolvation temperatures were 110 
°C and 400 °C, respectively, and the desolvation and cone gas flows were 252 and 76 L/h, 
respectively. Protonated molecular ions [M+H]
+
 and their respective product ions were 
monitored at the following transitions: 337 > 238 for CM304 and 318 > 220 for the IS. Argon 
gas was used as the collision gas. The collision energy for fragmentation of the precursor ions 
was set at 29 eV for CM304 and internal standard. The dwell time was set at 500 ms.  
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2.3.2. Determination of Log PO/W, Log DPBS, pH 7.4 and solubility 
The partition coefficient (Log P) itself is a constant. It is defined as the ratio of 
concentration of a neutral compound in aqueous phase to the concentration in an immiscible 
solvent. Log D is the log distribution coefficient at a particular pH. This is not constant and will 
vary according to the protogenic nature of the molecule. Log D at pH 7.4 is often quoted to give 
an indication of the lipophilicity of a compound at the pH of blood plasma. A stir-flask method 
was used for the determination of Log PO/W and Log DPBS, pH 7.4 of CM304 [108]. For the Log 
PO/W determination, water was used as the aqueous phase. Whereas for the Log DPBS, pH 7.4 
determination phosphate buffer saline (pH 7.4) was used as the aqueous phase. Equal quantities 
(10 mL) of n-octanol and water/PBS (pH 7.4) were added to a glass vial (25 mL). The contents 
were sealed using parafilm and stirred continuously on a VWR Dylastir magnetic stirrer for 24 h 
at room temperature (25 °C) to achieve mutual saturation of the two phases. The saturated phases 
were then separated using 1 mL pipette (Eppendorf, Hamburg, Germany) and poured in to fresh 
glass vials. A known quantity (1 mg) of CM304 was weighed and transferred in to a 4 mL glass 
vial. To the vial 1 mL of the saturated aqueous phase (water/PBS, pH 7.4) was added. The n-
octanol phase (1 mL, saturated with aqueous phase) was then poured very carefully on top of the 
aqueous phase in order to avoid emulsion formation. The contents were then stirred with a 
Teflon-coated magnetic stirring bar on a VWR Dylastir magnetic stirrer for 36 h allowing 
equilibrium to be reached. The vial was then left undisturbed for 24 h allowing the two phases to 
separate on standing. An aliquot (100 µL) of the aqueous layer was removed and diluted (1000 
times) with water or buffer. A 10 µL aliquot of the diluted sample was injected in to 
UPLC/MS/MS for analysis. 
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The solubility of CM304 was determined in distilled water and in phosphate buffer saline 
(pH 7.4) using the standard shake flask method [109]. In this method, an excess amount of 
CM304 was added to 100 µL of the solvent in tightly capped glass vials. Samples were 
constantly agitated (100 rpm) at room temperature (25 °C) for 24 h in reciprocating shaking 
water bath (Precision Scientific, VA, USA) for uniform mixing. After 24 h the samples were 
centrifuged (AccuSpin 17R, Fisher Scientific, USA) and the supernatant was and analyzed using 
UPLC-MS/MS for CM304 content.  
2.3.3. Determination of the acid dissociation constant (pKa) by a potentiometric method 
The pKa of CM304 was determined using a potentiometric method [110]. A Mettler 
Toledo S20 SevenEasy pH Meter was used to record all the pH values. A solution of 0.01 M 
sodium hydroxide was prepared and the pH was measured as 11.8 at room temperature. 
Similarly, 0.01 M hydrochloric acid solution was prepared and the pH recorded as 2.1. A 1 mM 
solution of CM304 was prepared by dissolving 8 mg of CM304 in 25 mL of water. To this 
solution 0.1 mL of 0.01 M sodium hydroxide solution was added using a 0.2 mL pipette (Fisher 
Scientific, NJ, USA) and the change in pH was recorded. The procedure was repeated until a 
constant pH was obtained. Thereafter, 0.1 mL of 0.01 M hydrochloric acid was added 
continuously using a 100 µL pipette (Eppendorf, Hamburg, Germany) and the change in pH was 
recorded until a constant value is reached. The titration curves were then constructed by plotting 
the recorded pH versus volume of base/acid added. The intersection point of the curves was 
noted as the pKa of the compound. 
2.3.4. Microsomal incubation 
The in vitro metabolic stability of CM304 was assessed using liver microsomes 
(Invitrogen™, C USA) from mouse, rat and humans. A stock solution of CM304 (500 µM) was 
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prepared by dissolving the required amount (168 µg) of CM304 in 1 mL of Tris buffer. A 10 µL 
of stock solution was added to the 1 mg of liver microsomal (mouse, rat or human) preparation 
and incubated at 37 °C for 5 min before starting the reaction. The metabolic reaction was 
initiated by the addition of regenerating system and carried out at 37 °C in a shaking water bath 
for 60 min. The regenerating system was prepared by dissolving, magnesium chloride (3 mM), 
nicotinamide adenine dinucleotide phosphate (1 mM), glucose-6-phosphate (5 mM), and 
glucose-6-phosphate dehydrogenase (1 Unit/mL) in 100 µL Tris buffer (50 mM, pH 7.4). 
Aliquots (100 mL) of the incubation sample mixtures were collected at 0, 5, 10, 15, 30, 45 and 
60 min. The reaction was terminated by adding an equal volume (100 µL) of ice cold methanol 
to precipitate proteins. The samples were centrifuged for 10 min at 4 °C and the supernatant was 
analyzed using UPLC/MS/MS.  
2.3.5. Protein binding studies 
The extent of protein binding of CM304 in rat plasma was determined by ultrafiltration 
using the Centrifree micropartition system (Amicon, MA, USA) [111, 112]. The technique of 
ultrafiltration relies on centrifugal force to drive the unbound test compound (compound of 
interest) through a size-selective membrane. The Centrifree unit consists of a top (donor) 
chamber and a bottom (receiver) chamber separated by a semipermeable membrane with a 
molecular weight cut-off of 30-kDa. A stock solution of CM304 (1 mg/mL) was prepared in 
water. The stock solution was diluted with water to yield concentrations (working standards) of 
0.1 and 0.2 mg/mL. The working standards, 0.1 and 0.2 mg/mL, were further diluted with plasma 
(10 µL of working standard added to 990 µL of plasma) to obtain the final concentrations of 1 
and 2 µg/mL, respectively. An identical series of samples were prepared using ammonium 
acetate buffer (pH 7.4) to estimate the nonspecific binding of test compound to the apparatus. In 
29 
 
some cases the test compound may bind to the centrifree unit, resulting in an underestimation of 
the free fraction of the compound. The prepared plasma samples at a volume of 300 μL was 
added to the donor chambers of centrifree unit (n=3). Similarly ammonium acetate buffer (pH 
7.4) samples (300 μL) were added to the top wells of the centrifree unit. The samples were 
centrifuged (1500 g) at 37°C for 20 min in a Beckman rotor centrifuge. Aliquots of 10 μL 
(ultrafiltrate) from the bottom chamber were transferred to UPLC vials and analyzed. 
2.3.6. Preparation of calibration standards and quality control samples 
The stock solutions of CM304 and the IS were prepared in water to yield concentrations 
of 1 mg/mL (1 mg of compound dissolved in 1 mL of water). Appropriate volumes of stock 
solutions were serially diluted with water to obtain working standard solutions of CM304 
ranging from 30 to 30,000 ng/mL and an IS at 1 µg/mL. All these solutions were make fresh 
each week and stored at -20 °C until needed. The calibration standards were prepared by spiking 
blank rat plasma (100 µL) with a working standard solution to yield CM304 concentrations of 3, 
10, 50, 100, 500, 1000, 1500, 2000 and 3000 ng/mL. Quality control (QC) samples were 
prepared in the same way as the calibration standards, at concentrations of 7.5, 300 and 2526 
ng/mL, representing low, medium and high concentrations, respectively. 
2.3.7. CM304 extraction from plasma samples 
Rat plasma samples were stored at -20 °C and allowed to thaw at room temperature 
before processing. Protein precipitation with acetonitrile was used for the extraction of CM304 
and SN56 (internal standard) from plasma samples, including calibration standards and QC 
samples. An aliquot of 100 µL of rat plasma was mixed with the IS working solution (SN56, 1 
µg/mL) in a micro-centrifuge tube. Acetonitrile (600 µL) was added to these samples and the 
resulting mixture was vortexed for 10 min on a VWR Signature
®
 pulsing vortex mixer (VWR 
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Scientific Inc., Radnor, PA, USA). Following centrifugation for 10 min at 10,000 × g using an 
Accuspin Micro 17R centrifuge (Fisher Scientific, Pittsburgh, PA, USA), a fixed aliquot of the 
organic phase was transferred to another micro-centrifuge tube and evaporated to dryness in a 
vacuum oven (Precision Scientific, Winchester, VA, USA) at 25 °C. The residue was then 
dissolved in 100 µL of mobile phase, and vortex-mixed for 1 min. A 10 µL aliquot of the 
solution was injected into the UPLC-MS/MS for the analysis. 
2.3.8. Method validation 
Bioanalytical methods employed for the quantitative determination of new compounds in 
biological fluids plays an important role in the determination and interpretation of 
pharmacokinetic study data. The quality of PK studies greatly depends on the quality of the 
underlying bioanalytical data. Therefore, the developed bioanalytical method needs to be 
validated to confirm that it will continue to provide accurate, precise, and reproducible data 
during study-sample analysis. Method validation demonstrates that the method will successfully 
meet the standards recommended by the USFDA Guidelines for bioanalytical method validation. 
A thorough and complete method validation of CM304 determination in rat plasma was 
performed as per the United States Food and Drug Administration (US-FDA) Bioanalytical 
Method Validation Guidance [113]. The method was validated for selectivity, recovery, matrix 
effect, linearity, precision, accuracy, and stability. 
2.3.8.1. Selectivity 
The selectivity was investigated by comparing the chromatograms of blank rat plasma 
with the corresponding spiked plasma samples. Six lots of blank rat plasma were screened for 
potential endogenous interferences at the retention times of CM304 and the IS. 
31 
 
2.3.8.2. Recovery and matrix effects 
The recovery and matrix effect of CM304 was determined at 7.5, 300 and 2526 ng/mL 
concentrations. Recovery of the analyte and IS was determined by comparing the peak areas of 
the analytes from QC samples (n=6) with those obtained from corresponding standards injected 
directly into the mobile phase. 
To determine if matrix effects exist, six different blank rat plasma samples were used to 
prepare the QC samples. The matrix effect was evaluated by comparing the average peak areas 
of analyte in spike-after-extraction samples to those obtained from corresponding standards 
injected directly into the mobile phase. 
2.3.8.3. Linearity and lower limit of detection 
Linearity was determined using nine concentrations of CM304 in the range of 3-3000 
ng/mL. The calibration curve was constructed by plotting CM304/IS peak area ratios versus 
nominal concentration of CM304 in plasma. The correlation coefficient and linear regression 
equations were used for the determination of CM304 concentration in the samples. 
The LLOQ was defined as the lowest concentration in the calibration curve with 
acceptable precision (RSD, below 20%) and accuracy (100 ± 20%.). The LLOQ was evaluated 
by analyzing six replicates of plasma samples (3 ng/mL) on three consecutive days. The limit of 
detection (LOD) was defined as the lowest concentration in a sample that can be detected but not 
quantified. The LOD was determined using a signal-to-noise ratio (S/N) of 3. 
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2.3.8.4. Accuracy and precision 
Intra- and inter-day accuracy and precision were evaluated by analyzing six replicates of 
QC samples at three different concentrations (7.5, 300 and 2526 ng/mL). For intra-day assay 
accuracy and precision, QC samples were extracted (as explained in section 2.3.7) and analyzed 
using a freshly prepared calibration curve on the given day. For inter-day assay accuracy and 
precision, the same procedure repeated over three consecutive days. The precision of the method 
was evaluated from the percent relative standard deviations (RSD%) of the concentration 
measurements, while accuracy was obtained by expressing the mean of the measured 
concentrations as a percentage of the nominal concentration. The evaluation of precision was 
based o n the criteria that the RSD for each concentration should be not more than ±15%. 
Similarly, for accuracy, the mean value should not deviate by more than ±15% of the actual 
concentration. 
2.3.8.5. Stability 
The stability of CM304 in rat plasma was assessed by analyzing six replicates of QC 
samples at concentrations of 7.5, 300 and 2526 ng/mL. Freeze-thaw stability was assessed by 
subjecting the unprocessed QC samples to three freeze-thaw cycles. Each freeze-thaw cycle 
consisted of storing the QC samples at -20 
o
C for 24 h then thawing at room temperature, after 
which the samples were refrozen for 24 h at -20 °C. The short-term temperature stability was 
determined by storing the unprocessed QC samples at room temperature for 12 h, which exceeds 
the routine preparation time of the samples. The long-term stability was determined after storage 
of the unprocessed QC samples at -20 ºC for 30 days. The stock solution stability of CM304 and 
IS was evaluated at -20 ºC for one week. At the end of all cycles the samples were processed, 
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analyzed and compared with the freshly prepared QC samples. To evaluate the auto-sampler 
stability, the reconstituted (post extracted) samples were stored in auto-sampler (maintained at 25 
°C) for 12 h. After 12 h samples were analyzed and compared with the freshly prepared QC 
samples.   
2.3.9. Pharmacokinetics of CM304 in rats 
Animal experiments were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the University of Mississippi. Male 
Sprague-Dawley rats (n=6) weighing approximately 200-250 g were used to estimate the 
pharmacokinetics of CM304 following intravenous (IV) and oral administration. Right jugular 
vein cannulated rats (Harlan Laboratories, Indianapolis, IN, USA) were housed in metabolic 
cages and allowed free movement and access to water during the entire experiment. The 
intravenous formulation (CM304 solution, 2 mg/mL) was prepared with saline and was dosed to 
the rats at 2.5 mg/kg. The IV formulation was prepared on the day of dosing and was 
administered via the jugular vein cannula as IV bolus. After that, the cannula was flushed with 
0.2 mL heparinized saline to ensure complete administration of the dose. The oral formulation 
was prepared with HPLC water and was dosed to rats at 20 mg/kg by oral gavage. The 
administered doses did not cause any notable toxicity in the animals. 
The blood samples were collected at 0 (pre-dose), 1, 3, 5, 10, 15, 30, 45, 60, 120, 180, 
240, 360 and 480 min after IV administration and at 0 (pre-dose), 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 
12 and 24 h after oral administration. An initial blood volume of 0.02 mL was withdrawn to clear 
heparinized saline present in the cannula. Using a fresh syringe 0.2 mL of blood sample was 
collected and placed in a micro-centrifuge tube, after which the same volume of heparinized 
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saline was injected. Plasma was separated by centrifugation at 10,000 × g for 10 min at 4 °C and 
transferred into clean micro-centrifuge, then stored at -20 °C until analysis. 
2.3.10.  Rapid metabolite identification using MetaboLynx 
Metabolite identification of the CM304 was performed using MetaboLynx software. 
MetaboLynx is a spectral/chromatographic search program associated with the MassLynx 
instrument/ data management program. It has been designed specifically to detect and identify 
metabolites for in vitro and in vivo drug metabolism studies. MetaboLynx compares the mass 
spectral chromatograms of a control sample versus a metabolized sample, and automates the 
detection, identification and reporting of metabolites. The rat liver microsomal stability study 
samples were used for the metabolite identification process. 
2.3.11. Characterization of CM304 metabolites using UPLC-MS/MS 
Metabolite separation, identification and characterization are important processes in the 
discovery and development of a new drug candidate. This process should be conducted as early 
as possible for several reasons:  
1) By identifying the metabolite(s) of a compound, one may uncover the metabolic “weak spots” 
on a molecule which helps in optimization of a lead molecule via chemical modifications.  
2) In some instances, biotransformation of a compound can convert in to a pharmacologically 
active metabolite or toxicologically active metabolites. The knowledge of active metabolites 
assists in the establishment of better pharmacokinetic/pharmacodynamic correlations.  
3) Pharmacologically active metabolites can be synthesized and developed as potential drugs 
themselves. 
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Tandem mass spectrometry is capable of rapidly identifying metabolites with 
characteristic sub-structures without the necessity of baseline separation of each compound 
[114]. The metabolite identification of the CM304 was performed using UPLC-MS/MS. The 
identification of metabolites using MS/MS is based on the assumption that most metabolites 
retain much of their original scaffolding and undergo the same fragmentation pattern as the 
parent compound. The structures of possible metabolites are characterized by interpreting their 
product ion spectra or comparing the product ion spectra and LC retention times with authentic 
standards [115]. 
The approach can be summarized as follows: 
(1) Obtain a product ion scan of a parent drug  
(2) Conduct precursor ion scans of the selected product ions obtained in previous step. This step 
provides the molecular ion information for the metabolites.  
(3) Obtain product ion scans of the identified metabolites. This step gives the information for 
characterization of the metabolite structures.  
3. Results and discussion 
3.1. In vitro metabolism studies  
The compound SN56, (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one), 
was previously reported to have high affinity (Kiσ1=0.56 nM) and preferential selectivity (>1000 
fold) for sigma-1 receptors over sigma-2 subtype. This compound was also tested against a wide 
battery of receptors (D1, D2, 5-HT, α1, α2, β1, β2, H1 and H2) and was found to have a moderate 
affinity towards the α2, and H1 receptors [107]. However, this compound suffers from poor 
metabolic stability in liver microsomal preparations (t1/2, 1.2 ± 0.2). In order to develop a 
metabolically stable compound a series of analogues (six) were synthesized with slight 
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modifications to the structure of SN56. These modifications were aimed to improve the 
metabolic stability while retaining its affinity and selectivity towards sigma-1 receptors. 
The compound RB6-55-11 was synthesized to inhibit the N-oxidation by adding a methyl 
group on second carbon of azepane ring. The compound RB7-310-19 was synthesized to prevent 
the hydroxylation of the two carbon chain linker between benzo[d]thiazol-2(3H)-one and 
azepane ring. Both RB-213-29, RB-79 and RB5-219-41 were synthesized to prevent oxidation at 
the benzylic carbon. As fluorine lowers the electron density on adjacent carbon and prevents 
certain reactions like oxidation,n CM304 was synthesized by incorporation of a fluoropropyl 
group in place of the propyl group of SN56. All the above compounds except CM304 were 
found to be very unstable in rat liver microsomes. The half-life and intrinsic clearance of CM304 
was found to be 5-fold higher than the other analogs. Moreover, the affinity and selectivity of 
CM304 towards sigma-1 receptors were found to be better than SN56 [116]. 
 
 
Compound Structure 
Half-life (min) ± 
SD 
CLint ± SD 
mL/min 
SN56 
 
1.2 ± 0.2 215.6 ± 18.8 
RB7-310-19 
 
1.3 ± 0.2 201.2 ± 21.3 
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Table 2.1: Metabolic stability of RB series of compounds in rat liver microsomes 
3.2. Preclinical characterization of CM304 
Compound CM304, (3-(2-(azepan-1-yl) ethyl)-6-(3-fluoropropyl) benzo[d]thiazol-2(3H)-
one), was found to have sub-nanomolar affinity (K iσ1, 2.5 pM) for sigma-1 receptors and more 
than 145,000 fold selectivity for sigma-1 receptors over sigma-2 receptors. Using NovaScreen 
and an in-house profile of 59 targets, CM304 displayed more than 100,000-fold selectivity for 
sigma-1 receptors compared to other tested targets [116, 117]. Moreover, this molecule exhibited 
RB6-55-11 
 
1.5 ± 0.1 187.5 ± 11.1 
RB-213-29 
 
1.8 ± 0.4 162.9 ± 36 
RB-79 
 
1.9 ± 0.1 147.6 ± 5.8 
RB5-219-41 
 
1.5 ± 0.1 188.2 ± 14.1 
CM304 
 
12.6 ± 1.9 22.5 ± 3.47 
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good stability in microsomal metabolic stability studies. The observed half-life of CM304 was 5-
fold longer than that of other tested ligands.  
CM304 was evaluated for its ability to inhibit/attenuate cocaine-induced convulsions 
(associated with cocaine overdose) in male Swiss Webster mice. Fisher’s exact tests were used to 
determine significant difference between the ratios of mice exhibiting convulsions or not, at each 
tested dose. The results indicated that CM304, like other putative sigma-1 receptor antagonists, 
significantly attenuated cocaine-induced convulsions at all doses examined (P<0.05, data not 
shown).  Another promising property of this molecule is having a fluorine atom on its methyl 
side chain. This feature aided in the development of a positron emission tomography (PET) 
imaging radio ligand for sigma-1 receptor binding studies. Fluorine-18 radiolabeled CM304 
([
18
F]FTC-146) was synthesized and tested in vitro and in vivo using positron emission 
tomography and the results from these studies suggested that [
18
F]FTC-146 is a potential 
radioligand for studying sigma-1 receptors in living subjects. PET images of [
18
F]FTC-146 in 
normal mice showed high uptake of the radioligand in the brain. Time activity curves (TACs) 
showed rapid, high initial uptake of [
18
F]FTC-146 in the mouse brain. Pre-treatment with CM304 
(1 mg/kg) 10 min prior to radioligand administration reduced the binding of [
18
F]FTC-146 in the 
brain (83% reduction at 60 min). These results suggested that [
18
F]FTC-146 accumulation in 
mouse brain represents specific binding to sigma-1 receptors. In the future, CM304 might 
emerge as a potential therapeutic candidate to treat cocaine over dose and its fluorine-18 
radiolabeled analogue ([
18
F]FTC-146) would be a promising new candidate for visualizing 
sigma-1 receptors in living subjects [117]. 
In this present work, experiments were performed for the preclinical evaluation of 
CM304 which includes estimation of its physicochemical properties such as acid dissociation 
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constant, LogPO/W and LogD PBS pH 7.4, in vitro metabolic stability studies in liver microsomes 
(mouse, rat and human) and protein binding studies. The detailed information of 
pharmacokinetics and drug metabolism of a new chemical entity should always be provided to 
support drug discovery and development. In order to estimate the pre-clinical pharmacokinetics 
of CM304, a rapid and sensitive bioanalytical method is needed. Here, we describe an analytical 
method for determination of CM304 concentrations in rat plasma using UPLC/MS/MS. The 
method was validated for selectivity, linearity, lower limit of quantification, precision, and 
accuracy. The molecular weight experimental pKa and Log D values indicates that CM304 
posses desirable physicochemical properties that are required for the BBB penetration. 
 
 
 
 
Figure 2.2: Chemical structure of CM304 
3.2.1. UPLC-MS/MS optimization 
The ionization and fragmentation of CM304 and the IS were obtained by infusing their 
respective solutions in to electrospray injection unit of a mass spectrometer at a constant flow 
rate of 10 µL/min. SN56 was chosen as the internal standard in the present method because of its 
similar chromatographic characteristics, ionization and it mimics CM304 in all sample 
preparation steps. The electrospray ionization of CM304 and the IS produced their protonated 
molecular ions, [M+H]
+
, at 337 and 318 under positive ionization mode. In order to obtain the 
intense molecular ion signals, several mass parameters were optimized which included cone 
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voltage, capillary voltage, ion energies, and entrance and exit widths. These protonated 
molecular ions undergo fragmentation in the collision cell. Several daughter ions were recorded 
but most abundant and stable fragment ion of m/z 238 for CM304 and m/z 220 for the IS and 
therefore were selected to monitor the transitions. The collision energy was investigated from 2 
to 30 eV to optimize the sensitivity of the product ions, and the optimal value was found to be 29 
eV for both CM304 and IS. The chemical structure, full-scan mass spectra of the protonated 
molecular ions and product ions of CM304, and the IS are shown in Fig. 1. Chromatographic 
analysis of CM304 and the IS was initiated under isocratic conditions with an aim to develop a 
simple separation process with a very short run time. Various chromatographic conditions with 
different column chemistries (Acquity UPLC BEH C18, C8 and HILIC) and mobile phase 
compositions (methanol, acetonitrile, formic acid, acetic acid, ammonium formate and 
ammonium acetate) were investigated.  
An acquity UPLC BEH C18 column and a mobile phase consisting of 0.1% formic acid in 
water and 0.1% formic acid in methanol (50:50, v/v) were found to be optimal for the separation 
and ionization of CM304 and the IS. The retention times for CM304 and IS were 1.3 min and 2.9 
min, respectively. Very narrow and sharp peaks (width less than four seconds) were obtained 
resulting in a dramatic increase in the chromatographic sensitivity with an LOD of 1 ng/mL. 
The high sensitivity of the UPLC-MS/MS technique allowed us to use a very small volume of 
plasma (100 µL) for the quantification of CM304 in rats. Protein precipitation was utilized for 
the extraction of the analytes from the rat plasma samples. Ice-cold acetonitrile was used as a 
precipitating solvent in the sample preparation process. The instrumental parameters used for the 
analysis were detailed in section 2.3.1.  
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Figure 2.3: (a) Chemical structure and protonated molecular ion spectra of CM304, (b) Product 
ion spectra of CM304 
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Figure 2.4: (a) Chemical structure and protonated molecular ion spectra of IS, (b) Product ion 
spectra of IS 
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3.2.2. Lipophilicity, solubility and pKa 
The lipophilicity of a compound is commonly expressed by its Log Doct which is assumed 
to be related to membrane partitioning. The term Log Doct is the log of the ratio of the amount of 
compound in the organic phase compared to that in the buffer at a given pH (usually 7.4). It is 
predicted that for a compound to have CNS activity the optimal log DPBS, pH 7.4 should be in a 
range of 1 to 3. The Log PO/W and Log DPBS, pH 7.4 of CM304 were determined using the stir-flask 
method (n=6). The Log PO/W and Log DPBS, pH 7.4 were found to be -0.15 ± 0.05 and 1.45 ± 0.04, 
respectively. In spite of the presence of lipophilic groups in the structure of CM304, the 
estimated log PO/W was found to be -0.15. This value indicates that CM304 has equal solubility 
towards aqueous and octanol phases. The dual solubility behavior of CM304 was explained by a 
phenomenon calling “self-coiling” [118]. A molecule possesses self-coiling due to hydrophobic 
collapse or hydrophilic folding. As a result of hydrophobic collapse and/or hydrophilic folding, a 
compound may become more hydrophilic in polar solvents and more lipophilic in non polar 
solvents. In effect, such compound to some extent adapts its lipophilicity to that of medium 
[118]. The solubility of CM304 in water (pH 5.6) and in phosphate buffer saline (pH 7.4) was 
found to be 165 and 72 mg/mL, respectively. The pKa was determined using potentiometric 
method and was found to be 10.4 indicating that the compound is basic in nature. Compounds 
with azepane ring in their structure, usually have a pKa between 9-10. The self-coiling nature of 
the CM304 might be reason for its high pKa value.  
Compound Log P O/W ± SD Log D PBS, pH 7.4 ± SD 
CM304 -0.15 ± 0.05 1.45 ± 0.04 
 
Table 2.2: Partition coefficient of CM 304 in octanol/water and octanol/ PBS, pH 7.4 (n=6) 
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Figure 2.5: pKa determination of CM304 
3.2.3. Metabolic stability of CM304 in mouse, rat and human liver microsomes 
Metabolic stability of CM304 was assessed in mouse, rat, and human liver microsomes. 
After incubation, the in vitro half-life (t1/2), intrinsic clearance (CLint), and major determinants 
for in vivo drug efficacy, were calculated. In order to calculate these parameters the percent of 
the parent compound remaining versus time was plotted figure 2.5. The slope of the initial 
portion of the line gives the rate constant k for the disappearance of parent compound.  
                                  t1/2 = 0.693/k 
CLint (microsomal) can be calculated using the following formula: 
 
                     CLint = k (min
-1
)   x   Incubation volume (mL)        
   Protein per incubation (mg) 
 
CLint (whole liver) was calculated from intrinsic clearance data (microsomal) using following 
equation: 
CLint (whole liver) = CLint (mL/min/mg) × MPPGL (mg/g) × Liver weight (g) 
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MPPGL: Microsomal protein per gram liver (mg/g): 45. 
Average Liver weight (g) in rat: 9.0 g. 
The results of the metabolic stability studies of CM304 are showed in Figure 2.6. In 
mouse liver microsomes the half-life of CM304 depletion was approximately 4 min, which is 3-
and 5-fold shorter than that in rat and human liver microsomes, respectively. These results 
indicate that CM304 was very unstable in the presence of phase I metabolizing enzymes 
(cytochrome 450s). The species differences in metabolic stability of CM304 might be due to 
variation in CYP isoforms in different species [119].  
 
Figure 2.6: Metabolic stability profiles for CM304 in mouse, rat and human liver microsomes 
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Figure 2.7: In vitro half-life (t1/2) of CM304 in mouse, rat and human liver microsomes 
3.2.4. Plasma protein binding studies 
The technique of ultrafiltration relies on centrifugal force which drives the unbound test 
compound through a size-selective membrane. The degree of nonspecific binding of the test 
compound to the Centrifree
®
 device was determined prior to investigating plasma protein 
binding. If the nonspecific binding exceeds 5%, ultrafiltration is not recommended for the 
determination of plasma protein binding. The percentage plasma protein binding was calculated 
according to the following equation: 
                                                             (Concentration of ultrafiltrate × 100) 
Plasma protein binding (%) = 100 – [                                                              ] 
                                                                         (Concentration added) 
CM304 was bound to the plasma proteins highly with 99.96% binding. Protein binding 
was independent of concentration. The nonspecific binding of the CM304 to the Centrifree
®
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device was found to be less than 0.4%, indicating that ultrafiltration is a suitable method for 
protein binding studies of CM304. 
3.2.5. Method validation 
3.2.5.1. Selectivity 
Six different lots of blank rat plasma were tested for any false positive MS/MS responses. 
The respective chromatograms of blank rat plasma, blank rat plasma spiked with CM304 and the 
IS are shown in Figure 2.7. The retention time of CM304 and the IS were 1.5 and 2.9 min 
respectively. The result showed the absence of any interference from endogenous plasma 
substances at the retention time of the CM304 and the IS. 
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Figure 2.8: (a) Chromatogram for blank plasma at m/z 337 > 237.5  (for CM304), (b) 
Chromatogram for blank plasma at m/z 318 > 219 (for internal standard), (c) Chromatogram for 
blank plasma spiked with 3 ng/mL CM304, (d) Chromatogram for blank plasma spiked with 100 
ng/mL IS. 
3.2.5.2. Recovery and matrix  
The mean recoveries and standard deviation of CM304 at low, medium, and high QC 
concentrations were 94.6±6.3%, 98.4±3.7% and 91.5±3.8%, respectively (mean±SD, n=6). Mean 
recovery for the IS was 91.2±6.1% at 100 ng/mL. The results indicated that the recovery of 
CM304 was consistent and was not concentration-dependent. The recovery of the IS was also 
consistent and reproducible.  
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The matrix effects on recovery of spike-after-extraction samples at 7.5, 300 and 2526 
ng/mL of CM304 were found to be 102.4±7.1%, 94.3±3.9% and 92.1±6.4%, respectively. The 
same evaluation was performed on the IS and the recovery was 96.6±4.3% at 100 ng/mL. The 
results showed that the matrix effects from endogenous plasma components on the ionization of 
the CM304 and the IS were negligible. 
3.2.5.3. Linearity, LLOQ and LOD  
The peak area ratios of CM304/IS versus the nominal concentrations of CM304 showed a 
good linear relationship over the concentration ranges of 3 to 3000 ng/mL in plasma. The typical 
regression equation of the calibration curves was:  
y = 0.0263x + 0.00984 (r
2
 = 0.999)  
y representing the peak area ratio of CM304 to the IS and x representing the concentration of 
CM304 in plasma. The RSD of the slope and intercept were 3.4 and 5.2, respectively. The LLOQ 
was found to be 3 ng/mL based on a relative standard deviation less than 20% and accuracy 
between 80-120%. The LOD was determined as 1 ng/mL
 
based on an S/N ratio of 3. 
 
Figure 2.9: Standard graph of CM304 in rat plasma 
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3.2.5.4. Accuracy and precision  
Intra- and inter-day accuracy and precision were determined from the analysis of QC 
samples (n=6) at concentrations of 7.5, 300 and 2526 ng/mL. The evaluation of precision was 
based on the criteria that the RSD for each concentration should be not more than ±15%. 
Similarly, the mean accuracy value should not deviate by more than ±15% of the nominal 
concentration. The intra- and inter-day RSD values were within 2.7% and 2.9%, respectively. 
Intra- and inter-day accuracies were between -0.4 to 1.8% and -1.9 to 1.3%, respectively. The 
results satisfactorily met the acceptance criteria and demonstrated that the developed method was 
reliable and reproducible. Table 2.3. summarizes the intra- and inter-day accuracy and precision 
values for quality control samples. 
Spiked   
concentration 
(ng/mL)  
Intra-day precision and 
accuracy (n=6)  
Inter-day precision and 
accuracy (n=6)  
   Measured 
concentration  
(mean ±SD, 
ng/mL) 
RSD 
(%)  
RE 
(%)  
Measured 
concentration 
 (mean ±SD, 
ng/mL) 
RSD 
(%)  
RE 
(%)  
7.5 7.5 ± 0.2  2.7 -0.4   7.6 ± 0.1  2.2 1.3 
300 305.3 ± 4.5  1.5 1.8   294.3 ± 8.6  2.9 -1.9 
2526 2542.4 ± 29.2  1.1 0.6     2533.3 ± 38.9  1.5 0.3 
     RSD. Relative standard deviation 
Table 2.3: Summary of the accuracy and precision of CM304 in rat plasma 
3.2.5.5. Stability 
The stability of CM304 was investigated at three concentrations of QC samples (7.5, 300 
and 2526 ng/mL) to cover expected conditions during analysis, storage and processing of all 
samples. The stability studies performed were freeze-thaw, short-term temperature, long-term 
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and auto-sampler stability tests. All the stability studies results except (Table 2.4) showed that 
CM304 was found to be stable after three freeze-thaw cycles, for 12 h at room temperature in rat 
plasma, and for 30 days at –20 °C. The stock solutions of CM304 and IS were found stable at –
20 °C for one week. Reconstituted samples were found to be stable after 12 h in auto-sampler 
which was maintained at 25 °C. 
Storage condition Concentration (ng/mL)   RSD  RE  
  Spiked   Measured          (%)    (%)   
Three freeze thaw cycles 7.5  7.3 ± 0.4 5.5  -3.3  
 300  331.3 ± 23.5 7.1  10.4  
 2526  2642.4 ± 110.2 4.2  5  
        
Long term for 30 days (-20 °C) 7.5  7.6 ± 0.2 2.6  1.3  
 300  306.4 ± 28.8 9.4  2.1  
 2526  2879.4 ± 209.8 8.8  -5.8  
        
Short term for 12hr (25 °C) 7.5  6.9 ± 0.9 13  -8  
 300  284.8 ± 17.8 6.3  -5.1  
 2526  2579.4 ± 243.1 9.4  2.1           
        
Auto sampler for 24hr (25 °C) 7.5  7.6 ± 0.7 9.2  1.9  
 300  313.6 ± 9.2 2.9  4.5  
  2526   2579.4 ± 145.2 5.6   -3.3   
Table 2.4: Results of various stability studies of CM304 in rat plasma 
3.2.6. Pharmacokinetics of CM304 in rats 
In this study, we explored the pharmacokinetics of CM304 in Sprague-Dawley rats (n=6) 
after a single intravenous and oral administration of 2.5 mg/kg and 20 mg/kg dose, respectively. 
The validated UPLC-MS/MS method was successfully applied to the determination of the 
plasma concentration profile of CM304 in rats. The mean plasma concentrations versus time 
profiles for CM304 after IV and oral administration were shown in Figure 2.9 and 2.10. 
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Pharmacokinetic analysis was performed using noncompartmental analysis with WinNonlin 5.2 
(Pharsight, CA, USA) software. The area under the plasma concentration-time curve from time 0 
to infinity (AUCinf) was calculated by the trapezoidal rule with extrapolation to time infinity. The 
terminal half-life (T1/2) was calculated as 0.693/λz, where λz is the terminal phase rate constant. 
The plasma clearance (CL) was calculated using the equation CL = Doseiv / AUCinf, iv, where 
Doseiv and AUCinf, iv are the IV dose and corresponding area under the plasma concentration-
time curve from time 0 to infinity, respectively. Volume of distribution based on terminal phase 
(Vd) was calculated using Vd = Doseiv/ (λz × AUCinf, iv). The peak plasma concentration (Cmax) 
and the time when it occurred (Tmax) in the oral dose group were obtained by visual inspection of 
the plasma concentration-time curves. Clearance after oral dose (CL/F) was calculated as Doseoral 
/ AUCinf, oral. Volume of distribution after oral dose (Vd/F) was calculated as 
Doseoral/(λz/AUCinf,oral). Oral bioavailability (F) was calculated using F = (AUCinf,oral × Doseiv) / 
(AUCinf,iv × Doseoral), where Doseoral, Doseiv, AUCinf, iv, and AUCinf, oral are the oral and IV dose 
and the corresponding areas under the plasma concentration-time curves from time 0 to infinity, 
respectively. The main IV and oral pharmacokinetic parameters of CM304 were shown in Table 
2.5 and 2.6, respectively. 
After IV administration of the compound to rats, the mean maximum plasma 
concentration (Cmax) of 2.1 ± 0.4 µg/mL was attained at 1 min (Tmax), while the AUC was 1412.2 
± 149.5 µg h/L. The volume of distribution (Vd) was found to be 5.9 ± 0.1 L/kg. The total 
clearance (CL) was found to be 2.0 ± 0.5 L/h/kg with an elimination half-life of 1.9 ± 0.3 h. Even 
though the half-life observed in the in vitro liver microsomal studies was very low (12 min), the 
IV administration CM304 showed good stability with a half-life of 115 min. This might be due 
to its high plasma protein binding nature and the rapid distribution of the compound into the 
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peripheral tissues. The estimated Log D PBS, pH 7.4 and pKa further supports its high distribution 
properties. These properties may limit the availability of CM304 for metabolism. The above 
properties might also be the reason for its low clearance value. After oral administration by 
gavage, a much lower amount of CM304 (Cmax, 26.4 ± 6.3 ng/mL) enters into the systemic 
circulation and detectable concentrations were observed until 6 h. The half-life (T1/2) of the 
compound was found to be 2 h and was calculated using the initial time points of the terminal 
elimination phase. The absolute oral bioavailability of CM304 in rats was found to be 0.7%. The 
low oral bioavailability might be due to the metabolism of CM304 by the GIT flora or gut wall, 
hepatic first pass metabolism and/or excretion into the feces. Furthermore, the study was done in 
fed state which might have affected the oral absorption. 
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Figure 2.10: Mean concentration of CM304 in plasma after IV administration versus time 
profile (n=8) 
Parameter    Mean ± SD  
T1/2 (h)   1.9 ± 0.3  
Cmax (µg/mL)   2.1 ± 0.4  
AUC0→t (µg h/L)   1412.2 ± 149.5  
Vd (L/kg)   5.9  ± 0.1  
CL (L/h/kg)   2.0  ±  0.5  
MRT (h)    1.9 ± 0.2  
 
Table 2.5: Pharmacokinetic parameters after intravenous administration of 2.5 mg/kg
 
CM304 to 
male Sprague Dawley rats (n=8) 
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Figure 2.11: Pharmacokinetic profile of CM304 after oral administration to rats at 20 mg/kg 
(n=8) 
Parameter    Mean ± SD  
T1/2 (h)   2.3 ± 1.2  
Tmax (min)  25.1 ± 12.2 
Cmax (ng/mL)   26.4 ± 6.3  
AUC0→t (µg h/L)   78.1 ± 31.4  
Vd (L/kg)   692.6 ± 86.7 
CL (L/h/kg)   260.3  ±  119.8 
 
Table 2.6: Pharmacokinetic parameters after oral administration of 20 mg/kg CM304 to male 
Sprague Dawley rats (n=6) 
 
 
 
1 
10 
100 
0 100 200 300 400 
M
ea
n
 o
f 
p
la
sm
a
 c
o
n
c.
 (
n
g
/m
l)
 
Time (min) 
56 
 
3.2.7. Rapid metabolite identification  
For the metabolite identification studies, 50 µM of CM304 was incubated with the rat 
liver microsomes (100 µL). The samples were then assayed after 2, 5 and 15 min of incubation in 
rat liver microsomes (as previously described in section 2.3.4.). Metabolite separation was 
accomplished using a linear gradient UPLC method with a mobile phase containing 0.1% formic 
acid in water (A) and 0.1% formic acid in acetonitrile (B). The linear gradient elution program 
was as follows: 0-80% B over 6 min, followed by an isocratic hold at 80% B for another 4 min. 
At 10 min, B was returned to 0% in 2 min and the column was equilibrated for 3 min before the 
next injection. The total run time for each injection was 15 minutes and the flow rate was 0.2 
mL/min. The column temperature was maintained at 25 °C and the injection volume was set at 
10 μL.  
The study samples were analyzed using UPLC-MS/MS and the zero min sample was used as the 
control. The chromatogram of control sample was compared with the 2, 5, and 15 min samples. 
Post-acquisition data were processed using MetaboLynx software.   The MetaboLynx software 
identified a wide range of metabolites with intense peaks at m/z 318, m/z 352, m/z 369 and m/z 
239. The results indicated that hydroxylation, dihydroxylation, defluorination and N-
oxidation/N-dealkylation might be the major metabolic pathways of CM304. 
Time 
(min) 
Flow rate 
(mL/min) 
% A % B 
0 0.2 0 100 
6 0.2 20 80 
10 0.2 20 80 
12 0.2 0 100 
15 0.2 0 100 
 
Table 2.7: Gradient method for metabolite identification 
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Figure 2.12: MetaboLynx output browser showing metabolites of CM304 
Based on the preliminary metabolite identification studies on CM304 the possible 
biotransformation routes identified were. 
1) Hydroxylation on azepane ring 
2) N-oxidation, N-dealkylation 
3) Deflourination 
4) Hydroxylation on hydrocarbon side chain 
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Figure 2.13: Possible biotransformation sites on CM304 
3.2.8. Identification and characterization of CM304 metabolites 
A daughter ion scan than precursor ion scan followed by product ion scan are the steps in 
characterization of the metabolites. In parent ion scan, the mass of the selected daughter of the 
parent compound is set and the parent is scanned over a range of masses such as 50-500 Da. In 
daughter ion scan, the parent mass is set and the daughters which resulted from collision induced 
dissociation (CID) are scanned to identify likely metabolites. 
The positive ion mass spectrum of CM304 showed an [M+H]
+
 ion at m/z 337.  The CID 
of the m/z 337 generated a series of product ions at m/z 238, 210, 190 and 162 (Figure 2.13). By 
using the precursor ion scan of m/z 162, we were able to detect some of the major metabolites of 
CM304. The interpretation of the daughter ion mass spectra of the precursor ions m/z 353 (M1 
and M2) and 369 (M3) and was addressed as follows. 
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M1 and M2  
The fragmentation ions of M1 and M2 were similar to each other which indicated that 
these two metabolites have a very similar structure. The chromatographic retentions times of M1 
and M2 metabolites were 6.4 and 7.9 min respectively. 
The product ion spectra at m/z 353 showed the most abundant fragment ion at m/z 238, 210, 190 
and 162 like the parent compound. This fragmentation pattern indicates that most of the CM304 
structure remains stable except azepane ring. Hydroxylation (16 Da) on azepane ring might be 
the possible structure for these metabolites.  
M3  
The [M+H]
+
 ion of M3 at 369 was 32 Da higher than that of parent compound CM304. 
The product ion spectra at m/z 369 showed the most abundant fragment ion at m/z 238 and the 
remaining fragment ions are similar to that of parent compound, thus confirming the occurrence 
of carboxylic acid metabolite. Possible routes of metabolism is the hydroxylation of the 2-
position of the azepane ring. Then the cycloalkylamine (azepane) ring will open to give an 
aldehyde which will further oxidize into an acid. 
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Figure 2.14: Daughter ion spectra of CM304, m/z 337 
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Figure 2.15: Chromatogram and daughter ion spectra of m/z 369 (M3)  
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Figure 2.16: Chromatogram and daughter ion spectra of m/z 353 (M2 and M3) 
 
 
m/z 0 50 100 150 200 250 300 350 
% 
0 
100 
238.0 
210.1 
190.1 
162.0 125.1 
(M2) 
 
m/z 
0 20 6
0 
100 140 180 220 260 300 340 
% 
0 
100 
238.1 
210.2 
125.3 190.1 237.7 
162.1 
(M1) 
Time 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 
% 
0 
100 Daughters of 353ES+  
5.73e6 
5.27 
6.49 
63 
 
 
 
 
Figure 2.17: Possible biotransformation routes and structures of the CM304 metabolites 
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4. Conclusion 
Based on metabolic stability in in vitro liver microsomal stability studies, CM304 was selected 
as a lead compound from a series of SN56 analogues. The experimental pKa and Log D values 
indicates that CM304 posses desirable physicochemical properties that are required for the BBB 
penetration. A bioanalytical method was developed and validated for the determination of 
CM304 in rat plasma. Intravenous pharmacokinetics in rats demonstrated its high distribution in 
to tissues. This could be a promising property for a molecule to develop as a PET imaging agent 
of sigma-1 receptors. The absolute bioavailability of CM304 was found to be 0.7%. Poor 
absorption, metabolism by the GIT flora or gut wall, hepatic first pass metabolism might be 
reasons for its very low bioavailability. The possible biotransformation routes were identified 
using MetaboLynx software. Three major metabolites of CM304 were identified using UPLC-
MS/MS.  
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CHAPTER - 3 
PHARMACOKINETICS OF MITRAGYNINE, A NATURALLY OCCURRING OPIOID 
AGONIST, IN RATS 
 
3.1.Introduction 
Mitragyna speciosa Korth, family Rubiaceae, is a tropical plant indigenous to Southeast 
Asia, particularly Thailand, Malaysia and Indonesia, where it is commonly known as Kratom or 
Biak-Biak [120]. The leaves of the plant have been used by the natives for their opium- and 
coca-like ability to combat fatigue and enhance tolerance to hard work under the scorching sun 
and also as a replacement for opium [121].  Furthermore, the leaves have been used to treat pain, 
cough, fever, hypertension and diarrhea. It is also reported to be self-administered by humans to 
alleviate the withdrawal symptoms of morphine-like drugs [120, 122]. The most common ways 
of consuming Kratom are chewing, eating the dried or fresh leaves, or by brewing the dried 
leaves into a tea [123]. Use of Kratom is illegal in Thailand, Malaysia, Myanmar (Burma) and 
Australia but it is currently not scheduled in the United States and Europe [124, 125]. The 
widespread availability of Kratom on the Internet reflects the extensive demand for this product 
and is indicative of an emerging trend to use Kratom as an alternative to other opioid-
replacement medications [122, 125]. The availability of Kratom over the Internet is of more 
concern due to the poor understanding of the chemical components and pharmacology of such 
products. Very little information is known about specific chemical constituents or combination 
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of compounds present in these products. The open availability of Kratom products to adolescents 
and young adults is factor for understanding the chemistry, pharmacology and toxicology of 
these crude herbs. Due to its unique medicinal properties, a number of chemical and 
pharmacological studies have been carried out on Kratom over the last five decades [126, 127]. 
Several indole alkaloids have been isolated and a preliminary study of the antinociceptive 
activity of the major constituent has been reported [128]. 
More than 40 alkaloids have been isolated from Kratom leaves to date. Of these 
mitragynine, an indole alkaloid, is the major component (66% of the crude base) and has been 
reported to be responsible for the therapeutic properties found in this plant [123, 129-131]. The 
pharmacological effects of mitragynine have been extensively investigated in animals [130, 132-
134]. Mitragynine displays in vitro activity at supraspinal opioid receptors (mainly through µ 
and δ opioid receptor subtypes). The µ receptor mediates analgesia, euphoria, and respiratory 
depression, which accounts for the analgesia activity of mitragynine, as well as its 
amelioration of opiate withdrawal symptoms. Mitragynine has also been proposed to be 
involved in the activation of descending noradrenergic and serotonergic pathways in the 
spinal cord to exert antinociceptive activity. However, there are no reports of mitragynine 
being screened for affinity at these specific sites [132-134]. Some pharmacological 
experiments revealed that mitragynine mediates analgesia through the blockade of neuronal Ca
+2
 
channels [130]. In addition to the pharmacological studies, two total syntheses of mitragynine as 
well as general structure-activity relationships (SARs) with respect to opioid activity have been 
published [131, 135, 136]. Interestingly, the reported effects of mitragynine in humans are dose-
dependent: lower doses result in stimulant effects, and higher doses result in opioid-like effects. 
These effects have also been witnessed in animal models. However, there is little information 
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about the mitragynine toxicity and the dose required in humans to produce stimulation, 
analgesia, and toxicity [137, 138]. In animal models, mitragynine has been shown to cause less 
respiratory depression than other narcotics [139].  
Because of its potentially valuable therapeutic properties, extensive research on 
mitragynine is being conducted worldwide [140-144]. To further understand the pharmacokinetic 
profile and to be able to monitor the therapeutic effects of mitragynine, a sensitive and high 
throughput method with minimal sample preparation is necessary for routine analysis of 
mitragynine in biological samples. Janchawee et al. [145] developed an analytical method using 
HPLC separation with UV detection. The major limitations of this method were a lack of 
sensitivity (lower limit of quantification, 100 ng/mL), a complicated sample preparation and a 
long analysis time (10 min). Later, Moraes et al. [143] developed a sensitive HPLC-MS/MS 
method requiring a large injection volume (120 µL) and involving a complex procedure for 
sample preparation. This method also possesses long retention times (12.9 min). Recently, 
Parthasarathy et al. [146] reported a solid phase extraction method using HPLC coupled with UV 
detection. This method has an advantage of a shorter retention time but it suffers from certain 
drawbacks such as complicated (solid-phase extraction step), time consuming sample preparation 
and a detection limit of 50 ng/mL which may not be suitable for pharmacokinetic and 
metabolism studies. Among the published methods, only Parthasarathy et al. [146] reported the 
pharmacokinetics of mitragynine in rat plasma after Intravenous (IV) administration.  Although 
analytically sound, the methods described above are still not fast enough for high throughput 
sample processing. In the past few years ultra-performance liquid chromatography (UPLC) 
coupled with a mass spectrometer (MS) has demonstrated the ability to significantly reduce the 
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analysis time thereby increasing sample throughput while retaining both sensitivity and 
resolution [147].  
To evaluate the pharmacokinetics of mitragynine in rats, we have developed a simple and 
high throughput bioanalytical method using UPLC-MS. This work presents the IV and oral 
pharmacokinetic studies of mitragynine in rats and development of a bioanalytical method in rat 
plasma. The developed and validated method was used to analyze the plasma samples of IV and 
oral pharmacokinetic studies. We also estimated mitragynine accumulation in tissues after IV 
and oral pharmacokinetic studies.  
3.2. Experimental 
3.2.1. Materials 
Mitragynine was extracted and purified (>99% pure) according to a published procedure 
in our laboratories [148]. Mitragynine was further purified by recrystallization from ethyl 
acetate/ethanol. The 
1
H NMR spectra of purified mitragynine agreed with data published 
previously [149] and the structure was further characterized through X-ray analysis [150]. The 
internal standard, amitriptyline hydrochloride, was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). All solvents used were HPLC grade. Formic acid was obtained from Mallinckrodt 
Baker Inc. (Phillipsburg, NJ, USA). Acetonitrile and water were purchased from Fisher 
Scientific (Fair Lawn, NJ, USA). Methyl t-butyl ether was purchased from EMD Chemicals Inc. 
(Darmstadt, Germany) and ammonium formate was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Rat plasma was purchased from Innovative Research (Peary Court Novi, MI, USA). 
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3.2.2. Instrument and Chromatographic Conditions 
The UPLC system consisted of a Waters Acquity UPLC (Milford, MA, USA) equipped 
with a binary solvent manager, vacuum degasser, thermostatted column compartment, and an 
auto sampler. Chromatographic separations were performed on a Waters Acquity UPLC
TM
 BEH 
HILIC column (1.7 μm, 2.1 × 50 mm). The mobile phase consisted of 10 mM ammonium 
formate buffer containing 0.1% formic acid:acetonitrile (15:85, v/v) and was pumped at a flow 
rate of 0.2 mL/min. The column temperature was maintained at 25 
o
C and the injection volume 
was 5 μL. These parameters resulted in a total run time of 3 min per injection. 
The mass spectrometer consisted of a Waters Micromass Quattro Micro
TM 
system 
(Manchester, UK). The system was controlled by MassLynx software version 4.0. Ionization was 
performed in the positive electrospray mode. The MS parameters for the analysis were as 
follows: capillary voltage 4.81 kV; cone voltage 40 V; extractor voltage 4 V and RF lens voltage 
0.5 V. The source and desolvation temperatures were 120 °C and 350 °C, respectively. The 
desolvation and cone gas flows were 300 and 60 L/hr, respectively. The selected mass-to-charge 
(m/z) ratio transition of mitragynine, amitriptyline ions [M+H]
+
 used in the selected ion 
recording (SIR) were as follows: mitragynine = 399.1 and amitriptyline hydrochloride = 278.3. 
The dwell time was set at 500 ms.  
3.2.3. Preparation of Calibration Standards and Quality Control Samples 
The stock solutions of mitragynine and amitriptyline hydrochloride (IS) were prepared 
with acetonitrile at a concentration of 1 mg/mL each. A series of working standard solutions of 
mitragynine at concentrations of 10, 50, 100, 500, 1000, 5000, 10000 and 50000 ng/mL and an 
amitriptyline solution at 1 µg/mL were prepared by appropriately diluting the stock solutions 
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with water. Calibration standards were prepared using blank rat plasma (100 µL) with working 
standard solutions of mitragynine and IS to yield the concentrations of 1, 5, 10, 50, 100, 500, 
1000 and 5000 ng/mL. Quality control (QC) samples were prepared by the same process as the 
calibration samples, at concentrations of 2, 400 and 4000 ng/mL, representing low, medium and 
high concentrations, respectively. 
3.2.4. Sample Preparation for Analysis 
Plasma samples, including calibration standards and QC samples, were extracted using 
methyl t-butyl ether. For analysis, 10 µL of IS solution (amitriptyline, 1 µg/mL) was added to an 
aliquot of 100 µL of rat plasma containing mitragynine in a micro-centrifuge tube. Methyl t-
butyl ether (500 µL) was added to these samples and the resulting mixture was vortexed for 10 
min on a VWR Signature
®
 pulsing vortex mixer (VWR Scientific Inc., USA). The samples were 
centrifuged at 3000 rpm for 10 min using an Accuspin Micro 17R centrifuge (Fisher Scientific, 
USA). A fixed aliquot of the organic phase was then separated and dried in a vacuum oven 
(Precision, Jouan Inc, USA) at 25 °C. The residues were then reconstituted with 100 µL of water 
and an aliquot of 5 µL was injected onto the chromatographic column. 
3.2.5. Method Validation 
The method validation assays were performed as per the United States Food and Drug 
Administration (US-FDA) Bioanalytical Method Validation Guidance [113]. The validation of 
the UPLC-MS method included: selectivity, recovery, matrix effect, linearity, lower limit of 
quantification (LLOQ), precision, accuracy, and stability studies. 
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3.2.5.1. Selectivity 
The selectivity of the UPLC-MS method was evaluated by comparing the chromatograms 
of six different batches of blank rat plasma with the corresponding spiked plasma samples at 
LLOQ. This determines the presence or absence of significant interfering peaks at the retention 
times of mitragynine and the IS. 
3.2.5.2. Recovery and Matrix Effects 
The recovery and matrix effects were determined by using six replicates of QC samples 
at concentrations of 2, 400 and 4000 ng/mL. The extraction recoveries were evaluated by 
comparing the peak areas of each compound after extraction with those obtained by direct 
injection of the same amount of analyte in water. The matrix effect was determined by 
comparing the peak areas of the analytes extracted from six different batches of rat plasma and 
the corresponding standards injected directly into the mobile phase. 
3.2.5.3. Linearity and Lower Limit of Detection 
To evaluate linearity, calibration standards of mitragynine at eight concentration levels 
(1, 5, 10, 50, 100, 500, 1000 and 5000 ng/mL)
 
were prepared. A calibration curve was 
constructed by plotting the peak area ratio of mitragynine/IS versus concentration of mitragynine 
in plasma. The correlation coefficient and linear regression equations were used for the 
determination of mitragynine concentration in the samples. The limit of detection (LOD) was 
defined as a parameter that provides the lowest concentration in a sample that can be detected but 
not quantified. The LOD was determined using a signal-to-noise ratio (S/N) of 3. The LLOQ was 
determined as the lowest plasma concentration that produced an S/N of 10 and could be 
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quantified with a relative standard deviation (RSD) lower than 20% and accuracy between 80-
120%. 
3.2.5.4. Accuracy and Precision 
Intra-day and inter-day accuracy and precision were evaluated by the analysis of six 
replicates of each QC sample at three different concentrations (2, 400, and 4000 ng/mL). For 
intra-day assay accuracy and precision, QC samples were processed as described in the sample 
preparation section and analyzed using a calibration curve prepared on the same day; for inter-
day assay accuracy and precision, QC samples were analyzed over three consecutive days. The 
evaluation of precision was based on the criteria that the RSD for each concentration should be 
not more than ± 15%, except for LLOQ, for which it should not be more than ± 20%. Similarly, 
for accuracy, the mean value should not deviate by more than ± 20% of the actual concentration. 
3.2.5.5. Stability 
The quality control samples (n=6), at three concentrations of 2, 400 and 4000 ng/mL, 
were used to carry out stability studies. For the freeze-thaw stability studies, unprocessed QC 
samples were subjected to three freeze-thaw cycles. Each freeze-thaw cycle consisted of storing 
the QC samples at -20 
o
C for 24 h then thawing them at room temperature, after which the 
samples were refrozen for 12-24 h under the same conditions. At the end of each cycle, the 
samples were processed, analyzed and compared with the freshly prepared QC samples. For the 
short-term temperature stability study, unprocessed QC samples were kept at room temperature 
for 12 h, which exceeds the routine preparation time of the samples. At different time points (3, 6 
and 12 h), the samples were processed, analyzed and compared with the freshly prepared QC 
samples.  
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3.2.6. Application to Pharmacokinetic Study 
The pharmacokinetic study was conducted using eight male Sprague Dawley rats (body 
weight 200 ± 50 g). All the experimental procedures were approved and performed in 
accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of 
the University of Mississippi. The rats were obtained from Harlan Company (Indianapolis, IN, 
USA), with previously inserted polyethylene cannulas into the right jugular vein. The rats were 
housed in metabolic cages and allowed free movement and access to water during the entire 
experiment. The intravenous (IV) formulation (mitragynine solution, 4 mg/mL) consisted of 1% 
cremophore EL in saline and was dosed to rats at 5 mg/kg. Oral formulation (pH 2.48) consists 
of HPLC water containing 0.1% of lactic acid and was dosed to rats at 20 mg/kg. Formulations 
were prepared on the day of dosing. The IV solution was administered via the jugular vein 
cannula as IV bolus, after which the cannula was flushed with 0.2 mL heparinized saline to 
ensure complete administration of the dose. The oral formulation was administered by oral 
gavage. All doses were pharmacologically effective and did not cause any notable toxicity in the 
animals. 
Blood samples were collected from each rat’s indwelling cannula at intervals of 0, 1, 3, 5, 
10, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 480 min after intravenous injection, whereas for 
the oral study the sampling was done at 0 min, 5 min, 10 min, 15 min and 0.5, 1, 2, 3, 4, 6, 7.30, 
8.30, 9, 12, 18, 24, 36 and 48 h after dosing. An initial blood volume of 0.05 mL was withdrawn 
to clear the line of heparinized saline. A fresh syringe was then used to withdraw a 0.25 mL 
blood sample that was placed in a micro-centrifuge tube, after which the cannula was flushed 
with 0.25 mL heparinized saline. Plasma was separated by centrifugation at 3000 g for 10 min at 
4 ºC and transferred into clean micro-centrifuge tubes and stored at -20 ºC until analysis. 
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3.2.7. Tissue accumulation 
After oral (48 h) and intravenous (8 h) pharmacokinetic studies, animals were 
anesthetized using ketamine intraperitonial injection. Lung, kidney, heart, pancreas and liver 
were collected after draining of the blood from anesthetized rats. Tissue samples were rinsed 
quickly after collection with NaCl (0.1 M) and homogenized in ice-cold water. A fixed aliquot of 
homogenate was subjected to liquid-liquid extraction with methyl t-butyl ether. During 
extraction, 400 µL of methyl t-butyl ether was added to 100 µL of tissue homogenate and 
vortrxed vigorously for 10 min. The organic supernatant layer was collected after centrifugation 
at 1000 g for 10 min and subjected to evaporation in a vacuum oven. The residue was 
reconstituted in 100 µL of water and aliquot 5 µL was injected onto the chromatographic 
column. 
The measured tissue concentrations (ng/ml) were converted to ng/gm of original tissues 
using the total volume of the homogenate and the original tissue weights. Mitragynine 
concentrations in tissue samples were determined by interpolation from standard curves prepared 
by spiking respective matrices with known concentrations of the compound and by analyzing 
them using UPLC-MS/MS. 
3.3.Results and Discussion 
3.3.1. UPLC-MS Optimization 
To date three methods have been published on the analysis of mitragynine in blood 
samples using the HPLC technique combined with UV and MS/MS detectors [143, 145, 146]. 
These methods were not suitable for high-throughput analysis of mitragynine and consumed 
large volumes of solvent. Using the developed UPLC method, the analyte retention time was 
75 
 
reduced from 4 to 1.3 min resulting in high sample throughput and minimum solvent 
consumption. Amitriptyline was chosen as the IS in the present method due to its similar 
chromatographic characteristics, ionization and no endogenous interferences at m/z 278.3 [143]. 
Mobile phase optimization was accomplished by comparing various solvent systems composed 
of mixtures of acetonitrile, formic acid, ammonium formate, ammonium acetate and acetic acid. 
The mobile phase consisting of mixture of 10 mM ammonium formate with 0.1% formic acid 
and acetonitrile (15:85, v/v) was found to be optimal for the separation and ionization of 
mitragynine and the IS. A 50 mm column was used with a flow rate of 0.2 ml/min resulting in a 
total run time of 3 min per sample. Very narrow and sharp peaks (width less than 2 s) were 
obtained resulting in a dramatic increase in the chromatographic sensitivity (LOD is 0.2 ng/mL). 
A liquid-liquid extraction technique was used for sample preparation. Several solvents 
(acetonitrile, methanol, chloroform and methyl t-butyl ether) were tested, and methyl t-butyl 
ether was selected due to high recovery and its faster drying rate. The optimization of the MS 
parameters was performed by directly infusing the solutions of mitragynine and amitriptyline (10 
µg/mL each) into the electrospray injection unit of a mass spectrometer at a constant flow rate of 
10 µL/min. The optimization was carried out in the electrospray positive ion mode. The mass 
spectra of mitragynine and the IS revealed base peaks at m/z 399.1 [M+H]
+
 and 278.3 [M+H]
+
, 
respectively. The instrumental parameters used for the analysis were detailed in section 2. 2. The 
Chemical structures and protonated molecular ion mass spectra of mitragynine and amitriptyline 
are shown in Figure 3.1. 
 
 
76 
 
 
 
Figure 3.1: Chemical structures and protonated molecular ion mass spectra of mitragynine (a), 
amitriptyline (b)  
3.3.2. Selectivity 
The UPLC-MS analysis of the plasma samples contained no interference from 
endogenous substances at the retention times of either mitragynine or the IS. The retention time 
of mitragynine and the IS were 1.3 and 1.5 min, respectively. There was a good base line 
separation of mitragynine and the IS extracted from the rat plasma. The respective 
chromatograms of blank plasma, blank rat plasma spiked with mitragynine and IS and the 
extracted plasma samples are shown in Figure 3.2. 
m/z 
50 100 150 200 250 300 350 400 450 500 550 600 
% 
0 
100 
278.3 
(b) 
m/z 
50 100 150 200 250 300 350 400 450 500 550 600 
% 
0 
100 
399.1 
400.2 
(a) 
77 
 
 
 
 
Time (min) 
1.00 2.00 3.00 
% 
0 
100 
1: SIR of 2 Channels ES+  
TIC 
2.11e6 
1.32 
1.55 
(e) 
Time (min) 
1.00 2.00 3.00 
% 
0 
100 
1: SIR of 2 Channels ES+  
278.3 
7.54e5 
1.55 (d) 
Time (min) 
1.00 2.00 3.00 
% 
0 
100 
1: SIR of 2 Channels ES+  
3.80e4 
1.32 (c) 
399.1 
Time (min) 
1.00 2.00 3.00 
% 
0 
100 1: SIR of 2 Channels ES+  
278.3 
220 
(b) 
Time (min) 
1.00 2.00 3.00 
% 
0 
100 
1: SIR of 2 Channels ES+  
399.1 
212 
 
(a) 
78 
 
Figure 3.2: (a) Chromatogram for blank plasma at m/z 399 (for mitragynine), (b) Chromatogram 
for blank plasma at m/z 278.3 (for internal standard), (c) Chromatogram for blank plasma spiked 
with 1.0 ng/mL mitragynine, (d) Chromatogram for blank plasma spiked with 100.0 ng/mL IS, 
(e) Chromatogram for plasma sample 30 min after intravenous administration mitragynine 
spiked with IS 
3.3.3. Recovery and Matrix 
The mean extraction recoveries were measured at three different concentration levels for 
mitragynine (2, 400, and 4000 ng/mL). This was accomplished by comparing the peak areas of 
mitragynine prepared in plasma with those obtained from direct injection of standards dissolved 
in water. The mean extraction recoveries were expressed as the percentage of the ratio of the 
mean peak areas of the analyte after extraction to the mean peak area of the analyte after direct 
injection. The mean recoveries of mitragynine at each QC level (2, 400, and 4000 ng/mL) were 
89.4 ± 10.4%, 85.1 ± 0.5%, and 92.3 ± 3.1% respectively, and the extraction recovery of the IS 
was 91.3 ± 3.2% at 100 ng/mL. The results indicated that the recovery of mitragynine and the IS 
was consistent and was not concentration-dependent.   
Co-eluting endogenous compounds may affect the ionization efficiency of the method. 
Therefore, matrix effects were also evaluated by comparing the peak areas of mitragynine 
extracted from the plasma QC samples to those obtained for the standards in the mobile phase at 
equivalent concentrations. The ratios obtained were 85.2 ± 7.5%, 89.3 ± 3.9% and 90.8 ± 1.1% at 
the concentrations of 2, 400 and 4000 ng/mL, respectively. The same effect was evaluated for the 
IS and the ratio was 89.6 ± 4.3% at 100 ng/mL. The results indicated that the matrix effects from 
endogenous plasma components on the ionization of the analytes were negligible.  
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3.3.4. Linearity, LLOQ and LOD  
A calibration curve (Figure 3.3) was constructed from the working standard mitragynine 
solutions at eight concentrations ranging from 1 to 5000 ng/mL. The ratio of peak areas of 
mitragynine to that of the IS was used for the quantification of mitragynine. The calibration 
curve was determined linear over the concentration range of 1 to 5000 ng/mL
 
with a correlation 
coefficient of 0.999 indicating good linearity. The calibration/regression equation of the 
calibration curve obtained from 8 points was y = 0.005x + 0.0059. The lower limit of 
quantification was found to be 1 ng/mL, with a relative standard deviation less than 20% and an 
accuracy of 80-120%. The LOD was determined as 0.2 ng/mL
 
based on a signal-to-noise ratio of 
3. 
 
Figure 3.3: Calibration curve of mitragynine in rat plasma 
3.3.5. Accuracy and Precision  
Intra-day and inter-day accuracy and precision were evaluated using the analysis of QC 
samples (n=6) at concentrations of 2, 400 and 4000 ng/mL. The accuracy and precision were 
determined by comparing the measured concentration to known concentrations using the 
y = 0.004x + 0.2953 
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calibration curve on the same day. For inter-day accuracy and precision, the same procedure as 
above was repeated for three consecutive days. The accuracy is expressed as a percentage value 
(% recovery) and the precision as a percentage relative standard deviation. The results of the 
inter-day and intra-day accuracy and precision are shown in Table 3.1. The intra-day precision 
for low QC, mid QC and high QC was found to be 1.8%, 0.1% and 0.6%, respectively, and the 
accuracy ranged from 101.0% to 102.9%. The inter day precision for low QC, mid QC and high 
QC was found to be 1.8%, 0.5% and 1.4%, respectively and the accuracy ranged from 100.5% to 
102.2% throughout the three concentrations. The results satisfactorily met the acceptance 
criteria. 
    R.S.D. Relative standard deviation 
Table 3.1: Summary of the accuracy and precision of mitragynine in rat plasma 
3.3.6. Stability 
The stability of mitragynine in rat plasma was assessed using six replicates of QC 
samples at three concentrations (2, 400, and 4000 ng/mL) under different storage conditions. The 
results of freeze-thaw and short-term temperature stability are shown in Table 3.2. Mitragynine 
was found to be stable after three freeze-thaw cycles and was stable for 12 h at room temperature 
in rat plasma.  
Spiked   
concentration 
(ng/mL) 
Intra-day precision and accuracy (n=6)  Inter-day precision and accuracy (n=6) 
 Measured 
concentration 
(ng mL
-1
) 
R.S.D. 
(%) 
Mean recovery  
(%) ± S.D. 
Measured 
concentration 
(ng mL
-1
) 
R.S.D. 
(%) 
Mean recovery 
(%) ± S.D. 
2 2.0 ± 0.1 1.8 102.8 ± 1.9  2.1 ± 0.1 1.9 102.2 ± 1.8 
400 405.1 ± 0.5 0.1 101.0 ± 0.1  406.6 ± 2.5 0.5 101.3 ± 0.5 
4000 4029.7 ± 6.6 0.6 102.9 ± 0.7  4005.0 ± 3.9 0.4 100.5 ± 0.4 
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  R.S.D. Relative standard deviation 
Table 3.2: Results of the short-term and freeze-thaw stability studies of mitragynine in rat 
Plasma 
3.3.7. In vivo pharmacokinetics of mitragynine 
The pharmacokinetics of mitragynine was evaluated in rats after IV and oral 
administration of 5 and 20 mg/kg dose, respectively. The mean plasma concentration-time 
profile for mitragynine after IV and oral administration were shown in Figure 3.4 and 3.5, 
respectively. A non-compartmental model was used to calculate the pharmacokinetic parameters 
with WinNonlin 5.2 (Pharsight, CA, USA) software. The corresponding results of the 
pharmacokinetic parameters are shown in Table 3.3 and 3.4. After IV administration, a 
maximum plasma concentration (Cmax) of 3.9 ± 0.7 µg/mL was achieved at 1 min. Thereafter, 
there was a rapid decline in the plasma concentration from 1 to 10 min indicating that the 
compound might have left the plasma and been distributed into the other tissues [151]. 
Parthasarathy et al. [146] reported the maximum plasma concentration (Cmax) at 1 h (Tmax). These 
authors reported plasma concentration of mitragynine starting at 20 min after IV administration 
  Concentration (ng/mL)      
  2   400   4000  
Stability Time (h)/ 
Cycle 
(times) 
Recovery 
(%) ± S.D 
R.S.D. 
(%) 
Recovery 
(%) ± S.D 
R.S.D. 
(%) 
Recovery 
(%) ± S.D 
R.S.D. 
(%) 
Short-time 
stability 
3 98.2 ± 2.4 2.4  99.6 ± 11.8 11.8  101.4 ± 2.0 2.0 
 
6 104.9 ± 3.8 3.6  91.3 ± 2.5 2.8  93.5 ± 3.8 4.1 
 12 87.8 ± 7.2 8.2  92.2 ± 3.3 3.5  87.5 ± 3.1 3.6 
          
Freeze-thaw 
stability 
1 95.1 ± 2.7 2.8  98.9 ± 1.3 1.3  107.8 ± 8.1 7.5 
 2 111.7 ± 5.5 4.9  100.2 ± 4.2 4.2  95.3 ±7.3 7.6 
  
3 97.2 ± 3.9 4.0   96.6 ± 2.3 2.4   109.1 ± 7.6 6.9 
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where as in our study we determined the mitragynine concentration from the first minute after 
administration. Thus, these authors may have missed the early rapid distribution phase of 
mitragynine into the tissues and could be a possible reason for the large variation in the Tmax. In 
the present study, we have completely dissolved mitragynine in 1% cremophor and saline unlike 
the 20% tween 20 formulation used by the authors of the previous study. This variation in 
excipients may play a vital role in the observed differences in the pharmacokinetic parameters 
[152].  
The volume of distribution (Vd) was found to be 8.2 ± 2.2 L/kg which is 10 times higher 
than that was reported previously by Parthasarathy et al. [146]. This may be explained by 
saturation of plasma protein binding (dose in the present study is 3 times higher than the previous 
study), in addition to distribution into highly perfused tissues as a result of the lipophilic nature 
of mitragynine [153, 154]. The other reason could be an over estimation of drug plasma 
concentration due to the lack of UV detection specificity compared to MS [155]. The total 
clearance (CL) was found to be 1.2 ± 0.2 L/h/kg with an elimination half-life of 2.6 ± 0.4 h. The 
clearance found in this study is 4 times more than that reported by Parthasarathy et al. [146]. The 
lower clearance reported by the previous authors may be due to the lack of specificity associated 
with the UV detection which resulted in higher plasma concentrations and an under estimation of 
apparent clearance [143, 155]. The observed pharmacokinetic parameters after oral 
administration were very close to the values reported by Moraes et al. [143]. 
Following the oral administration of 20 mg/kg of mitragynine, the mean maximum 
plasma concentrations (Cmax), 0.4 ± 0.1µg/mL, was observed at 1.2 ± 0.8 h (Tmax). The clearance 
was found to be 7.4±0.1 L/h kg with a elimination half life of 5.3 ± 2.1 h.   The observed AUC (0-
∞) and volume of distribution (Vd) were 2.8± 0.5 µg h/mL and 55.4± 16.4 L/kg, respectively. The 
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high Vd of mitragynine after oral administration might be reason for its low clearance and longer 
half-life. The high volume of distribution indicates more compound distribution to 
peripheral tissues and thus poor access of drug compound to elimination processes. The 
calculated pharmacokinetic parameters after oral administration were consistent with those from 
a previous study by Moraes et al. [143]. Average Absolute oral bioavailability of mitragynine 
free base in rats was found to be 21 %. This low bioavailability might be due to incomplete 
absorption from GIT, metabolism of mitragynine by the GIT flora or gut wall, hepatic first pass 
metabolism, or excretion into the feces. 
 
 
 
 
 
 
 
 
 
 
84 
 
 
Figure 3.4: Mean concentration of mitragynine in plasma after IV administration versus time 
profile (n=8) 
Parameter Mean ± SD 
T1/2 (h) 2.6 ± 0.4 
Cmax (µg/mL) 3.9 ± 0.7 
AUC0→∞ (µg h/mL) 3.4 ± 0.9 
Vd  (L/kg) 8.2 ± 2.2 
CL (L/h kg) 1.2 ± 0.2 
MRT (min) 137 ± 18 
 
Table 3.3: Pharmacokinetic parameters after intravenous administration of 5 mg/kg mitragynine 
to male Sprague Dawley rats (n=8)  
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Figure 3.5: Mean concentration of mitragynine in plasma after oral administration versus time 
profile (n=8) 
Parameter Mean ± SD 
T1/2 (h) 5.3 ± 2.1 
Tmax (h) 1.2 ± 0.8 
Cmax (µg/mL) 0.4 ± 0.1 
AUC0→∞ (µg h/mL) 2.8 ± 0.5 
Vd  (L/kg) 55.4 ± 16.4 
CL (L/h kg) 7.4 ± 0.1 
MRT (min) 330 ±110 
 
Table 3.4: Pharmacokinetic parameters after oral administration of 20 mg/kg Mitragynine to 
male Sprague Dawley rats (n=8)  
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3.3.8. Tissue accumulation 
Mitragynine accumulated in the tissues even after 48 h of oral and 8 h of intravenous 
pharmacokinetic studies. The concentrations absorbed were presented in Table 3.5. These results 
further support its high distribution into tissues. 
Organ 
Concentration (ng/gm) ± SD 
after oral administration 
Concentration (ng/gm) ± SD 
after IV administration 
Lung 18.6 ± 9.5 78.9 ± 14.9 
Kidney 8.8 ± 4.6 29.4 ± 10.1 
Heart 30.3 ± 19.7 141.7 ± 39.1 
Pancreas 27.7 ± 16.6 40.6 ± 3.8 
Liver 29.2 ± 18.2 31.2 ± 11.5 
Table 3.5: Tissues concentrations of mitragynine after oral and IV pharmacokinetic studies 
3.4. Conclusion 
In this study, we determined the pharmacokinetics of mitragynine in Sprague Dawley rats after 
IV and oral administration of 5 and 20 mg/kg dose, respectively. For the quantification of 
mitragynine in rat plasma samples, we have developed a rapid, simple and highly sensitive 
method using UPLC-MS. The developed method was validated according to the FDA 
bioanalytical method validation guidelines. The sample preparation procedure involves a simple 
liquid-liquid extraction, and the analysis requires only 100 µL of plasma, which is advantageous 
in a pharmacokinetic study. Mitragynine distributed extensively in the body, which is evidenced 
by its high Vd after IV and oral administrations. Tissue accumulation study results further 
supports its high distribution into tissues. The high Vd might be reason for its low clearance and 
longer half-life. The absolute oral bioavailability of mitragynine in rats was 21%. These 
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experiments will lay the groundwork for further studies in order to better understand the 
pharmacokinetic profile of mitragynine.  
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CHAPTER - 4  
PRECLINICAL PHARMACOKINETICS AND BRAIN TO PLASMA RATIO OF 7 -
HYDROXYMITRAGYNINE, A µ-OPIOID AGONIST WITH POTENT 
ANTINOCICEPTIVE EFFECTS 
 
4.1. Introduction 
Morphine is a well-known and widely used analgesic for the clinical treatment of acute 
and chronic severe pain.  Although very popular, it has a number of adverse effects: respiratory 
depression, nausea, vomiting, constipation, tolerance and dependence. Many morphine-related 
derivatives have been synthesized to develop powerful analgesics without side effects. 
Nevertheless, most of the drugs that are in use clinically still suffer from the side effects similar 
to those possessed by morphine. The primary objectives of  research in the  opioid area are to 
understand the underlying biology of the endogenous opioid systems, the discovery of new 
analgesic drugs devoid of unwanted effects associated with morphine and the development of 
new therapies for the treatment of opioid addicts [156]. 
7-hydroxymitragynine is a minor constituent in the plant material of Mitragyna speciosa. 
The leaves of this herb have long been used in Thailand for its opium- and coca-like effects, and 
as a replacement for opium. In addition, it has been used as a traditional medicine for common 
illnesses such as coughing, fever, diarrhea, muscle pain, hypertension and to cure morphine 
addicts [157]. This medicinal plant contains many indole alkaloids. Mitragynine, a corynanthine-
like alkaloid, is the main constituent present in leaves (66% of the alkaloid content) [158]. 
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Though, the structure of mitragynine is different from morphine, in pharmacological studies 
mitragynine showed agonistic effects on opioid receptors [159]. Watanabe et al., compared the 
antinociceptive effect of Mitragyna speciosa and mitragynine in in vivo experiments, but the 
antinociceptive effect of mitragynine was less potent than that of the crude extract of Mitragyna 
speciosa [160]. This finding suggested that minor constituents of Mitragyna speciosa might have 
a very potent antinociceptive effect. Horie et al. studied the opioid agonistic effects of the 
constituents of Mitragyna speciosa using in vitro assays. Among them, 7- hydroxymitragynine, 
an oxidized form of mitragynine (hydroxyl group at the C7 position) showed the most potent 
effect. This suggests that the opioid effect of Mitragyna speciosa is mostly based on the activity 
of 7-hydroxymitragynine [157, 161]. The administration of 7-hydroxymitragynine to mice 
induced a potent and dose dependent antinociceptive effect in the tail-flick and hot-plate tests. 
These effects were more potent than that of morphine when subcutaneously or orally 
administered [157]. In guinea-pig ileum, 7-hydroxymitragynine inhibited electrically induced 
contraction through the opioid receptors. Isolated tissue studies and receptor binding assays 
revealed that 7-hydroxymitragynine has a higher affinity for µ-opioid receptors (mainly through 
μ1-opioid receptors) relative to the other opioid receptors [157, 162]. Furthermore, 7-
hydroxymitragynine is found to be 4.9-6.4 times less constipating than morphine at equi-
antinociceptive doses. Matsumoto et al., attempted to overlay the 7-hydroxymitragynine with 
morphine using molecular modeling techniques but were not successful. Therefore, it was 
concluded that 7-hydroxymitragynine may be interacting with opioid receptors in a different 
fashion than morphine [163]. Having a novel structural scaffold for opioid receptor affinity and 
activity, 7-hydroxymitragynine promotes further investigation of it as a novel lead compound for 
opioid studies. Several analogues of 7-hydroxymitragynine were synthesized and research is 
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going on to develop novel pharmacotherapies as a replacement for morphine. [164]. Although 
pharmacology of 7-hydroxymitragynine has been investigated, there was no pharmacokinetic 
data available to date. The objective of this work was to investigate the pharmacokinetics, 
bioavailability and extant of brain penetration of 7-hydroxymitragynine in rats. In order to 
evaluate the pharmacokinetic characteristics of 7-hydroxymitragynine after administration to 
animals, an UPLC-MS/MS method for the determination of 7-hydroxymitragynine in rat plasma 
was developed. Also the extant of brain penetration of 7-hydroxymitragynine by estimating its 
brain to plasma ratio in rats was determined. 
4.2. Experimental 
4.2.1. Materials 
7-hydroxymitragynine was synthesized from mitragynine by Dr. Christopher McCurdy’s 
research group, Department of Medicinal Chemistry, University of Mississippi, as previously 
reported. 7-hydoxymitragynine was analyzed by 
1
H NMR, 
13
C NMR, elemental analysis, HPLC 
and HR-MS, and was found to be pure more than 99%. Tryptoline (1,2,3,4-Tetrahydro-9H-
pyrido[3,4-b]indole), was used as an internal standard (IS), and was purchased from Sigma-
Aldrich (St. Louis, MO, USA). Acetonitrile, acetic acid, chloroform and water were purchased 
from Fisher Scientific (Fair Lawn, NJ, USA).  All solvents used were HPLC grade. Rat plasma 
was purchased from Innovative Research (Peary Court Novi, MI, USA).  
4.2.2. Chromatographic analysis 
A Waters Acquity ultra-performance liquid chromatography (Waters Corp., Milford, 
MA, USA) was used for the quantitation of the analytes. All chromatographic separations were 
achieved by using an Acquity UPLC
TM
 BEH C18 column (1.7 μm, 2.1 mm×50 mm) maintained 
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at 25 ºC. The mobile phase consisted of 0.1% acetic acid in water and 0.1% acetic acid in 
acetonitrile (10:90, v/v) and was pumped at a flow rate of 0.2 mL/min. 
A Waters Micromass Quattro Micro
TM 
triple quadrupole system (Manchester, UK) 
equipped with an electrospray interface (ESI) was used as the mass spectrometry detection 
system (MS/MS) for the analysis. The mass spectrometer was operated in the positive ESI mode. 
Mass spectrometer instrumental parameters were tuned to maximize the generation of the 
precursor and fragment ions by infusion of a solution of 7-hydroxymitragynine and IS into the 
ESI source at 10 µL/min. The capillary voltage of the ESI was 4.06 kV. The temperature of the 
source and desolvation system was maintained at 120 and 200 °C, respectively. Nitrogen was 
used as the nebulizer gas and argon was used as the collision gas. The cone voltage was 
maintained at 23 V. The collision energy was 27 eV.  Analysis was carried out in the multiple 
reaction monitoring mode (MRM). The precursor-to-product ion transitions were monitored at 
m/z 415→190 for 7-hydroxymitragynine and at m/z 173→144 for the IS. 
4.2.3. Calibration standards and quality control samples 
The stock solution of 7-hydroxymitragynine and the IS were prepared in acetonitrile at a 
concentration of 1 mg/mL each. For working solutions, the stock solution of 7-
hydroxymitragynine was diluted with water to obtain concentrations in a range of 100 to 40,000 
ng/mL. A working solution of tryptoline (internal standard) was prepared at a concentration of 1 
µg/mL in methanol. Blank rat plasma (100 µL) samples were spiked with working solutions 7-
hydroxymitragynine to get the final concentrations (calibration standards) of 10, 50, 100, 500, 
1000, 2000, 3000 and 4000 ng/mL. Quality control (QC) samples were prepared at 
concentrations of 20, 600 and 3200 ng/mL, representing low, medium and high concentrations of 
the calibration curve respectively. 
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4.2.4. Sample preparation 
After thawing at room temperature, the rat plasma (100 µL) samples were spiked with 10 
µL of the IS working solution and vortexed (VWR Scientific Inc., PA, USA) for 30 s in a 
microcentrifuge tube  (Fisher Scientific, PA, USA). The extraction solvent, chloroform (800 µL), 
was added to the mixture and vortexed for 15 min. After vortexing, the mixture was centrifuged 
using an accuspin Micro 17R centrifuge (Fisher Scientific, PA, USA) at 10,000 g for 10 min. A 
750 µL aliquot of the organic phase (chloroform) that is present below the plasma was then 
carefully transferred with a micropipette in to eppendorf (Fisher Scientific, PA, USA) and 
evaporated to dryness in a vacuum oven (Precision Scientific, VA, USA) at 25 ºC. The residue 
was reconstituted in 100 µL water-acetonitrile (10:90, v/v) and 10 µL was injected into the 
UPLC–MS/MS system. All of the QC samples were prepared following the above method. 
4.2.5. Method validation 
A thorough and complete method validation of 7-hydroxymitragynine in rat plasma was 
done following the FDA bioanalytical method validation guidelines [113]. The method was 
validated for selectivity, sensitivity, accuracy, precision, recovery, linearity, stability and matrix 
effect.  
The selectivity of the developed method was investigated for the assessment of potential 
interferences of analyte and IS from endogenous substances. Selectivity was evaluated by 
comparing the chromatograms of six different lots of non pooled blank rat plasma, with the 
corresponding spiked plasma samples with analyte and IS. 
The sensitivity of the assay was determined using LLOQ, the lowest concentration on 
calibration curve that produced a signal to noise ratio (S/N) of 10, with a relative standard 
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deviation (%RSD) and relative error (%RE) less than 20%. The LLOQ was evaluated by 
analyzing samples in six replicates on three consecutive days. The limit of detection (LOD) was 
defined as the amount of 7-hydroxymitragynine that produced a signal three times to noise (S/N, 
3).  
A calibration curve of 7-hydroxymitragynine was plotted with concentrations at 10, 50, 
100, 500, 1000, 2000, 3000 and 4000 ng/mL. Peak-area ratios of the 7-hydroxymitragynine and 
the IS were plotted against the corresponding concentrations to get the calibration curve. 
Assay accuracy and precision were assessed by quantitating the QC samples at three 
different concentrations representing the entire calibration curve range (20, 600, and 3200 
ng/mL). The accuracy was determined by comparing the calculated concentration to the 
theoretical concentration of the QC samples. The precision was determined by intra- and inter-
day relative standard deviation (%RSD) of the QC samples. Six replicates at each QC 
concentration were analyzed for the determination accuracy and precision. 
The matrix effects regarding the ionization of 7-hydroxymitragynine and the IS were 
determined at the three QC levels (20, 600 and 3200 ng/mL). For the determination of matrix 
effect 2 different sets of standards were prepared, first the blank plasma was extracted without 
adding any compound. To this extracted plasma, 10 µL of analyte and IS were added, diluted to 
100 µL with mobile phase and analyzed. Secondly, analyte and IS were added to blank plasma 
and extracted and then analyzed. The matrix effect was then calculated by comparing the peak 
area ratios of blank plasma samples spiked with analyte and the IS before extraction, with blank 
plasma samples to which 7-hydroxymitragynine and IS were added after extraction. 
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The extraction efficency of 7-hydroxymitragynine was determined at low, medium and 
high concentrations (20, 600, and 3200 ng/mL). For the determination of recovery the QC 
samples were extracted with choloroform. These extracted QC samples were analyzed and the 
peak area ratios were compared with peak area ratios of standards prepared in mobile phase. 
Recovery of the analyte and IS need not be 100%, should be consistent, and reproducible at 
different concentration levels. 
The stability of 7-hydroxymitragynine in rat plasma was evaluated using QC samples 
(20, 600 and 3200 ng/mL) in six replicates. The stability of 7-hydroxymitragynine was tested 
under the following conditions: (1) freeze–thaw stability in rat plasma through three freeze-thaw 
cycles (2) short-term stability in rat plasma at room temperature for 12 h (3) long-term stability 
in rat plasma stored at -20 ºC for 30 days (4) post-preparative stability during storage in the auto 
sampler at 25 ºC for 12 h. To determine freeze-thaw stability, QC samples were stored at -20 °C 
for 24 h, thawed at room temperature and refrozen for 12-24 h under the same conditions. This 
procedure was repeated for three cycles. At the end of cycles the stability samples were 
processed and analyzed. For the short-term temperature stability, QC samples were stored in six 
replicates at room temperature for 12 h. The samples were analyzed after 12 h and the results 
were compared with the freshly prepared QC samples. The post operative stability (auto-sampler 
stability) was assessed by re-analyzing the samples that were kept in the autosampler at 25 °C for 
24 h. For long-term stability, QC samples in replicates of six were stored at -20 °C for a period 
of 30 days. The samples were processed and, analyzed on the 30
th
 day and the results were 
compared with freshly prepared QC samples.   
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4.2.6. Pharmacokinetic studies 
The animal studies were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Mississippi. Male Sprague-Dawley rats (200-250 g) were obtained 
from the Harlan Company (Indianapolis, IN, USA), with inserted polyethylene cannulas into the 
right jugular vein. The rats were initially housed the institutional vivarium. The vivarium is 
controlled environment with the temperature maintained between 21-23 °C and humidity 
50±10%. The controlled animal room was programmed for a 12 h light/dark cycle. Prior to 
dosing the animals were moved to the procedure room. The rats were fasted for 12 h before 
dosing and for the first 4 h after dosing but had free access to water during the experiment. The 
animals were allowed access to food beginning four hours after dosing,   
Both intravenous (IV) and oral formulations were prepared using 10% polyethylene 
glycol 400 in water and were dosed to rats at 4 and 20 mg/kg, respectively. The compound 
formulations were prepared fresh just prior to the administration to the rats. The IV solution (0.2 
mL) was administered using a 1 mL syringe and 23 G x 1 inch needle via the jugular vein 
cannula as an IV bolus in less than 10 s and the oral formulation (0.5 mL) was administered by 
oral gavage in less than 30 s. The cannula was flushed with 0.2 mL heparinized saline to ensure 
complete administration of the intravenous dose. All doses were pharmacologically effective and 
did not cause any notable toxicity in the animals. Blood samples (180 µL) were collected 
through each rat’s indwelling cannula at intervals of 0, 2, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240 
and 480 min post IV dose. After administration of the oral dose the blood samples were obtained 
at 0, 5, 10, 20, 30, 45 min and 1, 2, 3, 4, 8, 12 and 24 h. After each blood sampling, catheter was 
flushed with 0.18 mL of heparinized saline solution (1mg/mL). The blood samples were put into 
a heparinized microcentrifuge tube (Milian, OH, USA) and immediately centrifuged at 10,000 × 
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g for 10 min at 4 ºC. An aliquot (100 µL) of plasma was transferred into 1.5 mL microcentrifuge 
tube (Fisher Scientific, PA, USA) and then stored at -20 ºC until analyzed.  The pharmacokinetic 
parameters were calculated based on the plasma concentration versus time curves using the 
WinNonlin software, version 5.2 (Pharsight, CA, USA). The calculations were performed using 
a noncompartment model.  
4.2.7. Brain to plasma ratio studies 
The central nervous system, like all body organs and tissues, is supplied by a blood 
vasculature network; however it is rather uniquely built. The capillaries in the brain have 
developed to closely control the transfer of ions, small and large molecules as well as cells 
between blood and brain. The brain capillaries serve as a dynamic interface, the so-called blood-
brain barrier (BBB) [165]. The BBB is composed of tightly sealed endothelial cells acting in 
concert with resident brain cells such as astrocytes [166]. It serves as a physical barrier and 
active filter that restricts and regulates penetration of molecules between into brain to maintain 
its homeostasis [167]. The ability to traverse these barriers is essential for pharmaceuticals 
designed to act within the CNS and their duration of action is dependent on remaining “behind” 
the barrier. The BBB remains one of the greatest challenges for the discovery and development 
of treatments for CNS disorders [168]. 
The development of drugs targeting the CNS requires accurate knowledge of the drug's 
brain penetration. CNS compounds should be able to achieve sufficient concentration-time 
profile in brain and yet not too high or too long as to elicit unwanted effects. Ideally, this 
information should be obtained as early as possible to focus further research on the compounds 
that reach the target organ. Of the various in vivo methods available to estimate the permeation 
across the BBB, the determination of the brain/plasma ratio in vivo is most widely accepted 
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method. Although methods like in situ brain perfusions or brain microdialysis may be applied in 
the context of assessing CNS penetration, they actually look at very different aspects in 
measurement. The in situ brain perfusion technique is related to the rate of brain penetration of 
the drug. Brain microdialysis measures the free (unbound) drug concentration in the plasma and 
brain interstitial fluid. Only the brain/ plasma ratio provides information regarding the extent of 
penetration of the compound into the brain [165]. 
4.2.7.1. Brain/Plasma ratio study for 7-hydroxymitragynine in rats  
Brain/Plasma ration for 7-hydroxymitragynine was determined at predetermined time 
points (10 min and 20 min) and three rats were used for each time point. Rats were administered 
a single 4 mg/kg intravenous dose (0.2 mL) of 7-hydroxymitragynine. The IV dosing solution 
was prepared just before the animal study and contained 10% polyethylene glycol 400 in water. 
Rats were anesthetized by intraperitoneal administration of 100 mg/mL ketamine solution (200 
µL), 10 min prior to compound administration. Blood samples (0.5 mL) were collected at 10 min 
and 20 min after the compound administration by cardiac puncture using 1 mL syringe. The 
blood was immediately transferred into heparinized microcentrifuge tubes and stored on ice until 
centrifuged. The collected blood was centrifuged for 10 min at 10000 × g and the plasma was 
transferred into a fresh plain microcentrifuge tube. The plasma samples were stored at -20 °C 
(Kenmore Refrigerator, MA, USA) until analysis. Immediately after blood collection, animals 
were perfused with 40 mL phosphate-buffered saline (PBS) though the heart.  The perfusion was 
continued until the blood was completely removed from the body, which was evidenced by the 
pale coloration of the organs. The skull was then cut open using bone rongeurs and surgical 
scissors, and whole brains were excised carefully and rinsed in PBS. The brains were weighed 
and stored at -20 °C until analysis. 
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For the quantification of 7-hydroxymitragynine, brains were thawed to room temperature 
and transferred to a 20 mL glass vial. To this 3 ml of water was added and the tissue 
homozinized using a tissue homozinezer, (Tekmark, OH, USA). The homogenate was then 
transferred to a fresh microcentrifuge tube (1.5 mL) and centrifuged at 1000 x g for 10 min to 
remove the entrapped air. To 100 µL of homogenate, 10 µL of IS was added and vortexed for 30 
s. The mixture was then extracted with chloroform (800 µL) by vortexing for 10 min and 
centrifuged at 10000 x g for 10 min. A fixed aliquot (725 µL) of the lower organic layer was 
collected after centrifugation and subjected to evaporation in a vacuum oven. The residue was 
reconstituted in 100 µL of water:acetonitrile (10:90, v/v) and aliquot of 10 µL was injected into 
the UPLC-MS/MS for the analysis. 
The concentration of 7-hydroxymitragynine in brain samples were determined by 
interpolation from standard curves prepared in blank brains (Pel-Freeze, AR, USA)with known 
concentrations of the compound. For the construction of standard graph seven concentrations 
0.1, 0.5, 1, 2, 5, 7, 10 µg were used. The standards were prepared in blank brain samples by 
spiking 10 µL of solutions of concentrations 1, 5, 10, 20, 50, 70 and 100 µg/mL, respectively. To 
this mixture, 10 µL of IS was added, vortexed for 30 s and extracted with choloroform (800 µL) 
by vortex mixing for 15 min. A fixed aliquot of organic phase (725 µL) was separated after 
centrifugation and was evaporated to dryness. The dried samples were reconstituted with 100 µL 
of mobile phase by vortex mixing for 2 min and analyzed using UPLC-MS/MS. Blood samples 
were extracted and analyzed using the method mentioned in the section 2.4.  
Experiments were done using atenolol and imipramine as negative and positive controls, 
respectively [168, 169]. The brain to plasma ratio of atenolol was determined in rats (n=3) at 30 
min.  Atenolol was administered to rats at a dose of 10 mg/kg by intraperitoneal route (0.2 mL). 
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After the administration of the drug, rats were anesthetized by intraperitoneal injection of 100 
mg/mL ketamine solution (200 µL). Blood samples (0.5 mL) were collected at 30 min by cardiac 
puncture using 1 mL syringe. The collected blood was immediately transferred into heparinized 
microcentrifuge tubes and centrifuged for 10 min at 10000 × g and the plasma was transferred 
into a fresh plain microcentrifuge tube. The plasma samples were stored at -20 °C until analysis. 
Immediately after blood collection, whole brains were excised carefully and rinsed in PBS. The 
brains were weighed and stored at -20 °C until analysis. 
For the quantification of atenolol, brains were minced with a tissue homozinezer and the 
homogenate was then centrifuged at 10000 x g for 10 min. To 100 µL of homogenate, 10 µL of 
amitriptyline (IS) was added and vortexed for 30 s. The mixture was then extracted with 
acetonitrile (500 µL) by vortexing for 10 min and centrifuged at 10000 x g for 10 min. After 
centrifugation a fixed aliquot (450 µL) of the organic layer was collected and subjected to 
evaporation in a vacuum oven. The residue was reconstituted in 100 µL of acetonitrile and 
aliquot of 10 µL was injected into the UPLC-MS/MS for the analysis. To the collected blood 
samples 10 µL of IS was added and extracted with 500 µL of acetonitrile. After extraction the 
mixture was centrifuged and organic phase (450 µL) was collected and evaporated to dryness. 
The residue was reconstituted with acetonitrile 100 µL and analyzed by UPLC/MS/MS. 
The B/P ratio of imipramine was determined in rats (n=3) at 3 h after the administration 
of the compound. Imipramine was administered to rats at a dose of 20 mg/kg intraperitoneally. 
The dose and time points were selected based on the previously published literature. Blood 
samples was collected at 3 h after dosing and immediately after that the brains were excised 
carefully, washed with PBS and stored at -20 °C until analysis. For the quantification of 
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imipramine, brain and plasma samples were extracted (same as atenolol extraction procedure) 
with acetonitrile and analyzed UPLC-MS/MS.    
4.3. Results and discussion 
As 7-hydroxymitragynine is a non polar compound we evaluated commercially available 
RPLC columns such as C18 and C8 and Atlantis. A double peak was observed with C8 column and 
peak shape on Atlantis column was tailed. After a series of trials, C18 column was considered to 
be optimal and being a non polar compound, 7-hydroxymitragynine retained well with good peak 
shapes on Waters Acquity UPLC
TM
 BEH C18 column (1.7 μm, 2.1 mm×50 mm). To obtain 
efficient ionization responses for 7-hydroxymitragynine and the IS, various mobile phases were 
tried. As 7-hydroxymitragynine is a basic compound, acidic modifiers such as acetic acid and 
formic acid were added for higher ionization and MS/MS response. Different concentrations of 
acetic acid and formic acid (0.05%, 0.1% and 0.2%) in aqueous and organic phases were tested 
to improve the chromatographic peak shapes and the MS/MS response. The MS/MS response of 
7-hydroxymitragynine using acetic acid was about 2 times higher than that obtained with formic 
acid. The results indicated that the addition of 0.1% acetic acid to aqueous phase and organic 
phase greatly (3 times) improved the MS/MS response of analyte and the IS. Acetonitrile was 
chosen as the organic phase as it resulted in a two times higher analyte response with lower 
background noise compared to methanol. Furthermore, the mobile phase led to low column back 
pressure because of the high organic content (90%). The optimized mobile phase consisted of 
0.1% acetic acid in water and acetonitrile (10:90, v/v) at a flow rate of 0.2 mL/min. Tryptolin 
was selected as the IS because its chromatographic behavior and extraction efficiency were 
similar to those of 7-hydroxymitragynine [170]. Under optimized UPLC condition, the 
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chromatographic retention times of 7-hydroxymitragynine and IS were 0.5 and 0.4 min, 
respectively. The total run time was 2.5 min. 
There were no significant interferences from endogenous compounds observed at the 
retention times of the analytes (Figure 4.2). A one-step liquid–liquid extraction procedure was 
used for the sample preparation. Several extraction solvents (acetonitrile, chloroform, 
dichloromethane, ethyl acetate and methyl tert-butyl ether) were tested to optimize recovery. 
Finally, chloroform was selected as extraction solvent due to high recovery (64%). The 
recoveries of 7-hydroxymitragynine with various solvents were showed in Table 4.1. 
Solvent 
%Recovery of 7-
hydroxymitragynine  
Acetonitrile 21 
Chloroform 64 
Dichloromethane 25 
Ethyl acetate  48 
Methyl tert-butyl ether 41 
Table 4.1: %Recoveries of 7-hydroxymitragynine with various solvents 
The MS/MS parameters were optimized to the maximum response for the 7-hydroxymitragynine 
and the IS using positive ion mode. Under positive electrospray ionization (ESI) condition, 
protonated molecular ions [M +H]
+
 of 7-hydroxymitragynine and the IS were observed. Mass 
spectrum of 7-hydroxymitragynine [M +H]
+
 m/z 415 and the IS [M +H]
+
 m/z 173 are shown in 
Fig. 1. The MS/MS transition of 415>190 for 7-hydroxymitragynine and 173>144 for the IS was 
selected. 
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Figure 4.1:  Chemical structures, protonated molecular ion spectra and Product ion spectra of 7-
hydroxymitragynine (a, b) and tryptoline (c, d), respectively. 
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4.3.1. Method validation 
Selectivity was assessed by comparing the chromatograms of six different batches of 
blank rat plasma. Chromatograms of the blank and spiked plasma samples are given in Figure 4. 
2. The retention times of 7-hydroxymitragynine and the IS were about 0.5 and 0.4 min, 
respectively. Endogenous peaks at the retention time of the analytes were not observed for any of 
the blank rat plasma batches indicating no significant endogenous interference during the 
detections. 
The recovery of 7-hydroxymitragynine at all the three QC concentrations and the IS from 
rat plasma was shown in Table 4.2.  Recovery was calculated by comparing the peak areas of 7-
hydroxymitragynine added into blank plasma and extracted using the chloroform with those 
obtained from 7-hydroxymitragynine spiked directly into the mobile phase at the corresponding 
concentrations. The mean recoveries of 7-hydroxymitragynine averaged 64% at three 
concentration levels. The mean recovery of the IS was found to be 71%. The recovery of an 
analyte and of the IS were consistent and reproducible.  
The presence of co-eluting compounds from the matrix may affect the ionization and 
detection of analytes. No difference was observed between the peak area ratios of the analyte and 
IS obtained when analyte and IS were added to blank rat plasma after extraction and before 
extraction. The matrix effect at three QC concentrations (20, 600 and 3200 ng/mL) of 7-
hydroxymitragynine was found to be 100.2%, 98.6% and 92.1%, respectively. The matrix effect 
for the internal standard was 93.1%. The results indicate that the effect of endogenous 
compounds on the ionization of analyte and IS was negligible. The variability in matrix effect of 
both analyte and IS, as measured by %RSD, was found to be less than 15%. The %RSD for 
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analyte was 3.9%, 3.1%, and 1.6% at QC concentrations 20, 600 and 3200 ng/mL, respectively 
and %RSD for IS was 2.1%. 
Calibration standards of 7-hydroxymitragynine at concentration levels of 10, 50, 100, 
500, 1000, 2000 and 4000 ng/mL were assayed and a standard graph was plotted with area ratios 
of analyte/IS vs concentration of analyte. A typical regression equation for the calibration curve 
was: y = 0.0213x + 0.0118 
Where y represents the peak area ratios of 7-hydroxymitragynine to the IS and x 
represents plasma concentrations of analyte. The %RSD of slope was 2.7 and the %RSD of the 
intercept was 5.6 (n = 6). The calibration curve was found to be linear over the concentration 
range from 10 to 4000 ng/mL resulting in a correlation coefficient r
2
 > 0.995. The Lower limit of 
quantification in rat plasma was 10 ng/mL with a precision (%RSD) below 20% and an accuracy 
(%RE) within ±20%. The LOD was estimated at 2 ng/mL.  
The intra- and inter-day precision and accuracy data at three concentrations of 7-
hydroxymitragynine were listed in Table 4.3. The intra-day precision (%RSD) ranged from 1.0% 
to 1.3%, and the inter-day precision ranged from 2.2% to 3.1%. The intra-day accuracy 
(expressed as relative error) ranged from -1.5% to 4.1% and the inter-day accuracy ranged from -
1.9% to 2.0%. According US-FDA bioanalytical method validation guidance the precision 
determined at each concentration level should not exceed 15% of RSD except for the LLOQ, 
where it should not exceed 20% of the RSD. For accuracy, the mean value should be within 15% 
of the actual value except at LLOQ, where it should not deviate by more than 20%. As all these 
values were found to be within limits specified by US-FDA, the established method has a 
satisfactory accuracy, precision and reproducibility. 
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QC samples of 7-hydroxymitragynine at three concentrations (20, 600, 3200 ng/mL) 
were used for stability experiments. The stability of 7-hydroxymitragynine was investigated to 
cover expected conditions during sample preparation and storage for all samples, which include 
freeze-thaw, short-term temperature, long-term and auto-sampler stability. According to USFDA 
bioanalytical method validation guidelines the relative standard deviation (%RSD) should not be 
more than 15% and relative error (%RE) should not be deviated ±15% for a compound at all 
tested storage conditions. The results (Table 4.4) indicated that 7-hydroxymitragynine was stable 
in plasma, for three cycles when stored at -20 ºC and thawed to room temperature, for 12 h at 
room temperature, and for 30 days at -20 °C. Reconstituted samples were found to be stable for 
12 h in an auto-sampler which was maintained at 25 °C. 
 
 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
173.1 > 144.1 
193 
(b) 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
415.2 > 190.2 
155 
(a) 
107 
 
 
 
 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
173.1 > 144.1 
4.72e4 
(f) 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
415.2 > 190.2 
5.61e4 
0.50 
(e) 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
173.1 > 144.1 
4.48e4 
(d) 
Time 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
% 
0 
100 MRM of 2 Channels ES+  
415.2 > 190.2 
2.11e4 
0.50 
(c) 
0.43 
0.43 
108 
 
Figure 4.2: (a) Chromatogram for blank plasma at m/z 415.2 > 190.2 (for 7-
hydroxymitragynine), (b) Chromatogram for blank plasma at m/z 173.1 > 144.1 (for internal 
standard), (c) Chromatogram for blank plasma spiked with 10 ng/mL 7-hydroxymitragynine, (d) 
Chromatogram for blank plasma spiked with 100 ng/mL IS, (e, f) Chromatogram for plasma 
sample 10 min after intravenous administration spiked with IS 
 
Figure 4.3: Standard graph of 7-hydroxymitragynine in rat plasma 
Concentration 
(ng/mL)  
 
Recovery (%) 
± SD  
  
RSD 
(%)  
20  64.5 ± 4.3  6.7 
600  62.0 ± 6.1  9.8 
3200  67.3 ± 6.3  10.5 
100 (IS)   71.3 ± 3.9   5.5 
Table 4.2: Recovery of 7-hydroxymitragynine and IS from spiked rat plasma (n=6) 
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Spiked   
concentration 
(ng/mL)  
Intra-day precision and 
accuracy (n=6)  
Inter-day precision and accuracy 
(n=6)  
   Measured 
concentration  
(mean ±SD, 
ng/mL) 
RSD 
(%)  
RE 
(%)  
Measured 
concentration 
 (mean ±SD, 
ng/mL) 
RSD 
(%)  
RE 
(%)  
20 20.8 ± 0.2  1.0 4.1   19.3 ± 0.1  2.2 1.3 
600 591.2 ± 3.1  0.5 -1.5   596.1 ± 8.6  2.9 -1.9 
3200 3236.0 ± 41.6  1.3 1.1     3262.7 ± 102.9  3.1 2.0 
    RSD. Relative standard deviation, RE. Relative error 
Table 4.3: Summary of the accuracy and precision of 7-hydroxymitragynine in rat plasma 
Storage condition 
Concentration (ng/mL)   RSD  RE  
  Spiked   Measured          
(%) 
   (%)   
Three freeze thaw cycles 20  20.4 ± 0.3 1.5  2.0  
 600  631.3 ± 40.2 6.4  5.2  
 3200  3312.5 ± 163.5 4.9  3.5  
        
Long term for 30 days (-20 °C) 20  19.6 ± 0.8 4.1  -2.0  
 600  610.4 ± 28.8 4.7  1.7  
 3200  3058.2 ± 320.4 10.5  -4.4  
        
Short term for 12 hr (25 °C) 20  20.3 ± 1.3  6.4  1.5  
 600  652.7 ± 17.8 2.7  8.8  
 3200  3289.4 ± 197.2 6.0  2.8           
        
Auto sampler for 12 hr (25 °C) 20  20.4 ± 0.7 3.4  2.0  
 600  568.3 ± 43.9 7.7  -5.3  
  3200   3194.2 ± 84.2 2.6   -0.2   
        RSD. Relative standard deviation, RE. Relative error 
Table 4.4: Results of different stability studies of 7-hydroxymitragynine in rat plasma 
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4.3.2. Pharmacokinetic studies results 
We investigated the pharmacokinetic characteristics and bioavailability of 7-
hydroxymitragynine in rats after a 4 mg/kg IV and 20 mg/kg oral dose. The validated method 
described above was used for the analysis of rat plasma samples. The plasma concentration-time 
profiles of a single IV and single oral dose of 7-OH mitragynine were shown in Figure 4.4 and 
Figure 4.5. A noncompartment model was used to calculate the pharmacokinetic parameters with 
the WinNonlin software. The results of the pharmacokinetic parameters are shown in Tables 4.5 
and 4.6. 
After an IV dose of 7-hydroxymitragynine, a mean maximum plasma concentration 
(Cmax) was found to be 3.0 ± 0.3 µg/mL. The plasma concentration of 7-hydroxymitragynine 
decreased bi-exponentially, and was eliminated from plasma with a terminal half-life of 
approximately 22.9 min. The initial rapid decline in the plasma concentration indicates that the 
compound might have left the plasma and been distributed into the other tissues. The volume of 
distribution and clearance were found to be 1595.8 ± 586.3 mL/kg and 44.2 ± 14.8 mL/min/kg, 
respectively. Immediately after IV administration, no movements were observed in rats and were 
motion less up to 20 min. After 20 min rats recovered fast and behaved normally over the entire 
study.   
After oral administration, the mean Cmax of 2.8 ± 0.3 was observed at 25.8 ± 6.6 min 
(Tmax). 7-hydroxymitragynine appeared rapidly in plasma after oral administration indicating that 
the absorption is fast form rats gastrointestinal tract. The 7-hydroxymitragynine was distributed 
extensively in the body with a volume of distribution of 3451.2 ± 856.0 mL/kg. A high clearance 
value was observed (91.4 ± 27.2 mL/min/kg) after oral dose. The high clearance resulted in a 
short terminal half-life of 27.1 min after oral administration. The absolute oral bioavailability 
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was found to be 52.2%. This low bioavailability might be due to metabolism of 7-
hydroxymitragynine by the GIT flora or gut wall, hepatic first pass metabolism, or excretion into 
the urine or feces. 
 
Figure 4.4: Mean concentration of 7-hydroxymitragynine in plasma after IV administration 
versus time profile (n=6) 
Parameter   Mean ± SD 
T1/2 (min)  22.9 ± 3.6 
Cmax (µg/mL) 3.0 ± 0.3 
AUC0→∞ (µg min/mL) 98.3 ± 32.1 
Vd  (mL/kg) 1471.7  ± 606.1 
CL (mL/min/ kg) 44.2  ±  14.8 
MRT (min)   70.9 ± 10.0 
 
Table 4.5: Pharmacokinetic parameters after intravenous administration of 4 mg/kg
 
7-
hydroxymitragynine to male Sprague Dawley rats (n=6) 
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Figure 4.5: Mean concentration of 7-hydroxymitragynine in plasma after oral administration 
versus time profile (n=6) 
Parameter 
  
Mean ± SD 
T1/2 (min)  27.1 ± 6.4 
Tmax (min)  25.8 ± 6.6 
Cmax (µg/mL) 2.8 ± 0.3 
AUC0→∞ (µg min/mL) 253.7 ± 61.5 
Vd  (mL/kg) 3451.2  ± 856.0 
CL (mL/min/ kg) 91.4  ±  27.2 
MRT (min)   175.0± 81.5 
 
Table 4.6: Pharmacokinetic parameters after oral administration of 20 mg/kg
 
7-
hydroxymitragynine to male Sprague Dawley rats (n=6) 
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4.3.3. Brain to plasma ratio studies 
 
 
Figure 4.6: Calibration curve of 7-hydroxymitragynine in rat brain tissues 
Dose (mg/kg) Time (min) 
  
Concentration 
  
B/P 
ratio 
    Brain (ng/gm) Plasma (ng/mL)  
4 10  6958.3 ± 447.1 1926.7 ± 146.4 3.6 
4 20  3572.4 ± 385.4 1135.1 ± 81.2 3.1 
Table 4.7: Concentrations of 7-hydroxymitragynine in plasma and brain; ratio between brain and 
plasma concentrations (n=3) 
Generally, the compounds with a brain/plasma ratio of greater than 1 are considered to 
have free access to the CNS and whilst the compounds with a value of smaller than 0.1 may 
unable to enter the CNS. The compounds with brain/plasma ration between 0.3- 0.5 have 
sufficient access to CNS. If the ratio considerably exceeds unity, i.e. the brain/plasma ratio is 
much greater than 1, the compound may accumulate in brain tissue, e.g. by binding to lipids, 
membranes, proteins or lysosomal trapping [165, 171]. 
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After IV administration, the brain to plasma (B/P) ratio of 7-hydroxymitragynine was 
found to be 3.4 ± 0.4. The high B/P ratio of 7-hydroxymitragynine indicates that it is freely 
crossing the BBB and accumulating in the brain tissues. The observed atenolol and imipramine 
B/P ratio values were consistent with the reported literature values [168, 169]. 
 
Figure 4.7: Calibration curve of atenolol in rat brain tissue 
 
Figure 4.8: Calibration curve of imipramine in rat brain tissue 
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Compound 
Route of 
administration 
Dose 
(mg/kg) 
Time 
(h) 
 Concentration  
B/P 
ratio 
    Brain (ng/gm) 
Plasma 
(ng/mL) 
 
Atenolol Intraperitoneal 10 0.5 39.3 ± 6.2 3118.1 ± 243.1 0.01 
Imipramine Intraperitoneal 20 3 3214.4 ± 421.2 201.1 ± 33.5 15.9 
 
Table 4.8: Brain to plasma ratio study results of atenolol and imipramine 
4.4. Conclusions 
The pharmacokinetic parameters and bioavailability of 7-hydroxymitragynine were 
investigated in rats after IV and oral administration of 4 and 20 mg/kg dose, respectively. By 
optimizing the chromatographic conditions, a sensitive and rapid bioanalytical method was 
developed and validated for the quantification of 7-hydroxymitragynine in rat plasma. It is the 
first report of UPLC/MS/MS method on the determination of 7-hydroxymitragynine 
concentration in vivo so far.  
After IV administration, 7-hydroxymitragynine was distributed extensively in the body 
which was evidenced by its rapid decline in the plasma concentrations and its high volume of 
distribution. We have estimated the brain to plasma ratio of 7-hydroxymitragynine after IV 
administration of 4 mg/kg dose, the dose which we have used for the evaluation of IV 
pharmacokinetics. The brain to plasma ratio was found to be high i.e. 3.4 ± 0.4 which indicates 
that 7-hydroxymitragynine freely crossing the BBB and accumulating in the brain tissue. The 
observed brain to plasma ratio further supports its high distribution in to highly perfused tissues 
like brain, liver and kidney etc. The above findings indicate that 7-hydroxymitragynine has the 
properties which are required for a compound acting on CNS. 
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After oral administration, 7-hydroxymitragynine absorbed rapidly through the GI tract in 
rats. The absolute oral bioavailability of 7-hydroxymitragynine was found to be 52%. Rapid 
absorption after oral administration (Tmax, 25.8 min) of 7-hydroxymitragynine indicates that the 
absorption is not an issue for the low bioavailability. The low bioavailability might be due to 
metabolism by the GIT flora or gut wall, hepatic first pass metabolism, or excretion into the 
urine or feces.  
Based on results of pharmacokinetic studies after IV and oral administration and brain to 
plasma ratio studies, 7-hydroxymitragynine is a promising lead compound for opioid studies. 
Synthesis of metabolically stable analogues of 7-hydroxymitragynine would be a good start in 
the development of novel therapeutics as a replacement for morphine and its analogues. It can 
potentially reduce the abuse of opioids. 
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CHAPTER - 5 
ANALYSIS OF KRATOM LEAVES AND MECONIUM SAMPLE RECEIVED FROM 
LOUISVILLE, KENTUCKY 
5.1. Introduction 
A baby boy was born (01/17/2012) with severe opioid withdrawal symptoms at a hospital 
in Louisville, Kentucky. The mother stated that she consumed the Kratom leaves, which were 
purchased over the internet. She also reported that she did not consume any other medications. 
To investigate the components that are responsible for the observed withdrawal symptoms in 
new born baby, a sample of the Kratom leaf material consumed by the patient and a sample of 
meconium, (the earliest stool) of new born were sent to our lab. Meconium is composed of 
materials ingested during the time the infant spends in the uterus. We investigated the samples 
for mitragynine, 7-hydroxymitragynine and possible opiate contamination using pure morphine 
and hydrocodone. 
 
Figure 5.1: Samples of Kratom leaves and meconium 
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5.2. Experimental 
5.2.1. Materials 
Pure mitragynine and 7-hydroxymitragynine were obtained from Christopher McCurdy’s, 
Department of Medicinal Chemistry, University of Mississippi. Purity of mitragynine and 7-
hydroxymitragynine were mentioned in the section 3.2.1 and 4.2.1, respectively.  Morphine 
sulfate and hydrocodone bitartrate were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
All solvents used were HPLC grade. Acetonitrile, acetic acid and water were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  
5.2.2. Instrumentation and analytical conditions 
The chromatographic separation was carried out on a Waters Acquity ultra-performance 
liquid chromatography (Milford, MA, USA). A Waters Acquity UPLC
TM
 BEH C18 column (1.7 
μm, 2.1mm×50 mm) was used for all the separations. The mobile phase consisted of 0.1% acetic 
acid in water and acetonitrile. It was pumped at a flow rate of 0.15 mL/min. The column 
temperature was maintained at 25 
o
C and the injection volume was 10 μL. The duration of the 
run was 17 min. The gradient method was able to separate mixture of mitragynine, morphine, 
hydrocodone and 7- hydroxymitragynine. When the pure sample mixture was injected the 
retention times for mitragynine, morphine, hydrocodone and 7-hydroxymitragynine were 
observed at 10.6, 1.6 and 4 and 10.1 min, respectively. Details of the gradient method are 
presented in Table 5.1. 
Mass spectrometric analysis was performed using Waters Micromass quattro Micro
TM 
triple-quadrupole system (Manchester, UK) equipped with an electro-spray ionization (ESI) 
119 
 
source. The system was controlled by MassLynx software version 4.1. The detection was 
achieved with ESI positive ionization using multiple reaction monitoring (MRM). The MS/MS 
parameters for the analysis were as follows: capillary voltage 3.5 kV, cone voltage 30 V, 
extractor voltage 1 V, RF lens voltage 0.5 V. The source and desolvation temperatures were 100 
°C and 400 °C, respectively, and the desolvation and cone gas flows were 400 and 100 L/h, 
respectively. Protonated molecular ions [M+H]
+
 and their respective product ions of 
mitragynine, morphine, hydrocodone and 7-hydroxymitragynine monitored at the following 
transitions: 399 > 174, 286 > 165, 300 > 199 and 415 > 190, respectively. Argon gas was used as 
the collision gas. The collision energy for fragmentation of the precursor ions was set at 30 eV. 
The dwell time was set at 500 ms. Chemical structures and product ion spectra of mitragynine, 
morphine, hydrocodone and 7-hydroxymitragynine are shown in Figure 5.2, 5.3, 5.4 and 5.5, 
respectively. 
 
Time 
(min) 
Flow rate 
(mL/min) 
% A % B 
0 0.15 95 5 
8 0.15 80 20 
14 0.15 10 90 
15 0.15 95 5 
17 0.15 95 5 
 
Table 5.1: Gradient method used for the Kratom leaves and meconium sample analysis 
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Figure 5.2: Chemical structure and product ion spectra of mitragynine, m/z 399 > 174  
 
Figure 5.3: Chemical structure and product ion spectra of morphine, m/z 286.1 > 165.1 
 
Figure 5.4: Chemical structure and product ion spectra of hydrocodone, m/z 300 > 199  
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Figure 5.5: Chemical structure and product ion spectra of 7-hydroxymitragynine, m/z 415.1 > 
190.1 
5.2.2. Sample preparation 
The Kratom leaves were grounded to fine power using a coffee bean grinder. The 
Powdered leaf sample (10 mg) was dissolved in 1 mL of water and methanol (50:50, v/v). The 
solution was vortexed (VWR Scientific Inc., PA, USA) for 10 min and then centrifuged using an 
accuspin Micro 17R centrifuge (Fisher Scientific, PA, USA) at 10,000 × g for 10 min.  After 
centrifugation, an aliquot (10 µL) of clear supernatant was injected in to the UPLC-MS/MS for 
the analysis. Meconium sample (0.5 gm) was added to 2 mL of water and methanol (50:50, v/v) 
in a glass vial. The resulting solution was vortexed for 10 min and then transferred in to an 
eppendorf tubes (Fisher Scientific, PA, USA) and the samples were subjected to centrifugation at 
10,000 × g for 10 min. After centrifugation, clear supernatant was collected, evaporated to 
dryness under nitrogen stream at 25 °C. The residue was then dissolved in 100 µL of water and 
methanol (50:50, v/v). A 10 µL aliquot of the solution was injected into the UPLC-MS/MS for 
the analysis.  
 
25-Jan-2012, 
13:07:51 
QAA926  
m/z 100 200 300 400 500 
% 
0 
100 
190.1 
175.
0 
110.0 162.1 
397.0 
226.2 
238.1 
415.1 
(d) 
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5.3. Results and discussions 
In the developed gradient method, the pure mitragynine, morphine, hydrocodone and 7-
OH mitragynine were eluted at 10.6, 1.6 and 4 and 10.1 min, respectively. The chromatograms 
of Kratom leaves and meconium samples were compared with the chromatograms of pure 
compounds (mitragynine, morphine, hydrocodone and 7-hydroxymitragynine). Figure 5.6, 5.7 
and 5.8 shows chromatograms of pure compounds, Kratom leaf extract and meconium samples, 
respectively. Mitragynine, hydrocodone and 7-hydroxymitragynine were found in the extract of 
leaves and no signs of morphine indicating that the Kratom leaf material might have been 
adulterated with hydrocodone. The hydrocodone present in the leaf material might be reason for 
the opiate withdrawal symptoms of the new born baby. We have analyzed the meconium sample 
of the baby. As hydrocodone eliminates primarily through kidneys, we did not find detectable 
concentration of hydrocodone in meconium sample. Only, Mitragynine and 7-
hydroxymitragynine were identified in the meconium sample.  
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Figure 5.6: Chromatograms of pure mitragynine (a), morphine (b), hydrocodone (c) and 7-
hydroxymitragynine (d)  
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Figure 5.7: Chromatograms of Kratom leaves extract at m/z 399>174 for mitragynine (a), m/z 
286>165 for morphine (b), m/z 300>199 for hydrocodone (c) and m/z 415>190 7-
hydroxymitragynine (d) 
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Figure 5.8: Chromatograms of meconium sample at m/z 399>174 for mitragynine (a), m/z 
286>165 for morphine (b), m/z 300>199 for hydrocodone (c) and m/z 415>190 7-
hydroxymitragynine (d) 
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5.4. Conclusion 
In the present work, we have developed an analytical method for the simultaneous 
analysis of mitragynine, morphine, hydrocodone and 7-hydroxymitragynine. The Kratom leaves 
and meconium sample were analyzed using the developed method. Mitragynine, hydrocodone 
and 7-hydroxymitragynine and were found in the Kratom leaf sample indicating that the Kratom 
leaf sample might have been adulterated with the hydrocodone. The severe opioid withdrawal 
symptoms absorbed in the baby might be because of 7-hydroxymitragynine and hydrocodone.  
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CHAPTER - 6 
SUMMARY AND CONCLUSIONS 
 
The first chapter is mainly related to therapeutics for cocaine abuse. Second and third 
chapters are focused on therapeutics for opioid abuse. Fourth chapter is a recent case study about 
opioid abuse. 
Cocaine abuse is a major public health problem and is responsible for more serious 
intoxications and deaths than any other illicit drug. Currently, there are no approved medications 
to aid in its treatment. Acute cocaine administration can cause euphoria, stereotyped behaviors, 
locomotor hyperactivity, and even lethality, depending on its dosage. Furthermore, repeated 
cocaine exposure may result in sensitizing and rewarding effects which are accompanied by 
neuroadaptations. Several studies have shown that cocaine preferentially exert its 
psychostimulant effect by binding to sigma-1 receptors. It is believed that, sigma-1 receptors 
influence the actions of cocaine through three different mechanisms, 1) direct binding to the 
receptors, 2) modulation of other neurotransmitter systems, and 3) alterations in gene expression. 
Hence, developing synthetic small molecule antagonists for S1Rs will be an effective strategy in 
the development of potential therapeutic candidate for cocaine abuse.  
CM304, (3-(2-(azepan-1-yl) ethyl)-6-(3-fluoropropyl) benzo[d]thiazol-2(3H)-one), is a 
highly selective sigma receptor antagonist with greater affinity for sigma-1 receptors. CM304 is 
a structural analogue of SN56, a benzothiazolone class of compound that was previously 
reported to have high affinity (Kiσ1= 0.56 nM) and more than 1000 fold selectivity for sigma-1 
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subtype relative to sigma-2.  CM304 was synthesized by slight modification to the structure of 
SN56 i.e. incorporation of a fluoropropyl group in place of the propyl group. This modification 
was aimed to develop a metabolically stable compound with little or no affect on its high affinity 
and selectivity for the sigma-1 receptors. Interestingly, CM304 was found to be superior to SN56 
in terms of affinity (Kiσ1=2.5 pM) and selectivity (>145,000) towards sigma-1 subtype compared 
to sigma-2. Moreover, in a NovaScreen and in-house profile of 59 targets, CM304 displayed 
more than 100,000-fold selectivity for sigma-1 receptors compared to other tested targets.  
CM304 was evaluated for its ability to attenuate cocaine-induced convulsions (associated with 
cocaine overdose) in mice. Similar to other putative S1R antagonists, CM304 significantly 
attenuated cocaine-induced convulsions in mice. This data is consistent with other reported S1R 
antagonists. In this present work, we performed preclinical evaluation of CM304 by evaluating 
its in vitro metabolism (using mouse, rat and human livermicrosomes) and in vivo 
pharmacokinetics in rats. We also estimated its physicochemical properties such as solubility, 
acid dissociation constant, Log PO/W and Log D PBS pH 7.4 and protein binding. The molecular 
weight (336), estimated pKa (10.4) and Log D (1.45) values indicates that CM304 possess 
desirable physicochemical properties required for a compound acting on CNS. Species 
dependent metabolic stability was observed in in vitro liver microsomal stability studies of 
CM304. The half life of CM304 in human liver microsomes was found to be high compared to 
the rat and mouse liver microsomes. This species differences in metabolic stability of CM304 
might be due to variation in CYP isoforms in different species. In order to evaluate the in vivo 
pharmacokinetic parameters in rats, a bioanalytical method was developed and validated for the 
determination of CM304 in rat plasma. After IV administration, the plasma concentration of 
CM304 decreased rapidly in first 15 min. The initial rapid decline in the plasma concentration 
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indicates its high distribution properties in to highly perfused tissues. Even though the half-life 
observed in the in vitro liver microsomal studies was very low (12 min), after IV administration 
CM304 showed good stability with a half-life of 115 min. The rapid distribution of the 
compound into the peripheral tissues and its high plasma protein binding nature might be reason 
for its longer half life. These properties may limit the availability of CM304 for metabolism. 
After oral administration, a very less compound entered in to the systemic circulation which is 
evident by its low mean maximum plasma concentration. The absolute oral bioavailability of 
CM304 was found to be 0.7%. Poor absorption, metabolism by the GIT flora or gut wall, hepatic 
first pass metabolism might be some of the reasons for its very low bioavailability. The possible 
biotransformation routes were identified using MetaboLynx software. Two hydroxylated and one 
carboxylic acid metabolites of CM304 were identified using various UPLC-MS/MS scans.  
Morphine, a phenanthrene opioid receptor agonist, is a well-known and widely used 
analgesic for the clinical treatment of acute and chronic severe pain.  Activation of the µ-opioid 
receptors located in the regions of brain and spinal cord are responsible for the majority of the 
physiological and behavioral effects of morphine. Although very popular, its narrow therapeutic 
index and severe side effects limit its therapeutic use. The most prominent side effects are 
respiratory depression, decreased gastrointestinal motility and the development of dependence, 
withdrawal symptoms after chronic administration. Many morphine-related derivatives have 
been synthesized to develop therapeutics devoid of abusive/addictive properties like morphine. 
The currently available semisynthetic and synthetic opioids have favorable properties than 
morphine but they still possess undesirable properties of morphine. 
Mitragyna speciosa Korth is a tropical plant indigenous to Southeast Asia. The leaves of 
the plant have traditionally been used by natives as a substitute for opium or to treat withdrawal, 
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as well as for their stimulant effects. Furthermore, the leaves have also been used by southern 
Thai villagers as a medicine to treat coughing, diarrhea, muscle pain and hypertension. 
Mitragynine and 7-hydroxymitragyne, corynanthine-like alkaloids, have been reported to be 
responsible for the opioid properties found in this plant. Though, the structures of mitragynine 
and 7-hydroxymitragynine were different from morphine, in pharmacological studies these 
compounds showed agonistic effects on opioid receptors.  Having a novel structural scaffold for 
opioid receptor affinity and activity, mitragynine and 7-hydroxymitragynine promote further 
investigation as novel lead compounds for the development of therapeutics for opioid abuse. To 
further understand the pharmacokinetic profile and to be able to monitor the therapeutic effects 
of mitragynine, a sensitive and high throughput method with minimal sample preparation was 
developed using UPLC-MS.  After IV administration, plasma concentration of mitragynine was 
decreased rapidly from 1 to 10 min which indicates that the compound might have left the 
plasma and been distributed into the other tissues. Mitargynine concentrations observed in 
tissues after IV and oral pharmacokinetic studies further supports its high distribution into 
tissues. The high Vd might be reason for its low clearance and longer half life after IV and oral 
administration. The absolute oral bioavailability of mitragynine in rats was 21%. Although 
pharmacology of 7-hydroxymitragynine has been investigated, there was no pharmacokinetic 
data available to date. We have evaluated the pharmacokinetics of 7-hydroxymitragynine in rats 
after IV and oral administration. 7-hydroxymitragynine was distributed extensively in the body 
after IV administration, which was evidenced by its rapid decline in the plasma concentrations 
and its high volume of distribution. We have also estimated the brain to plasma ratio of 7-
hydroxymitragynine after IV administration of 4 mg/kg dose. The estimated brain to plasma ratio 
indicated that 7-hydroxymitragynine was freely crossing the BBB and accumulating in the brain 
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tissue. The observed brain to plasma ratio further supports its distribution in to highly perfused 
tissues like brain. The observed high clearance after IV and oral administration might be reason 
for its shorter half life. 
In conclusion, CM304 serves as a metabolically stable lead compound in the 
development of potential therapeutic candidate to treat cocaine abuse. Mitragynine and 7-
hydroxymitragynine serve as promising lead compounds for opioid studies. Synthesis of 
metabolically stable analogues of mitragynine and/or 7-hydroxymitragynine would be a good 
start in the development of novel therapeutics as a replacement for morphine and its analogues. It 
can potentially reduce the use of abusive opioids. 
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